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ABSTRACT

There is a growing demand for non-surgical means of cataract treatment. This
dissertation presents three bodies of work that reflect the early-stage development of eye
drop formulations aimed at delaying cataract progression. These formulations consist of
the antioxidant 2-mercaptopropionylglycine (MPG) loaded onto nanodiamond particles.
Cataractogenesis is linked to oxidative damage to lens proteins. To investigate the
potential of MPG for protection against oxidative damage, A549 cells were incubated in
0.6 mM tert-butylhydroperoxide (tBHP). Cells exposed to tBHP without MPG exhibited
elevated levels of reactive oxygen species, which led to the depletion of the vital
antioxidant glutathione and, ultimately, apoptosis. Co-administration of 5 mM MPG
protected cells from tBHP-induced damage, resulting in maintenance of cell viability.
To monitor the uptake and fate of MPG in the eye, a rapid, high sensitivity HPLC
method was developed for the analysis of MPG and its metabolite, 2-mercaptopropionic
acid, in ocular tissues. Method validation experiments demonstrated the reliability of this
method for quantifying MPG uptake and evaluating drug delivery strategies.
Achieving effective drug concentrations in the lens poses a major challenge.
Nanodiamond is biocompatible, and its surface chemistry can be tailored to specific
applications. Thus, it is emerging as a candidate of interest for drug delivery.
Nanodiamond surfaces were functionalized with carboxyl (ND-COOH), hydroxyl (NDOH), and amino (ND-NH2) groups to investigate the effect of ND surface chemistry on
adsorption and release of MPG. The ND-NH2 exhibited the highest adsorption capacity,
but the ND-OH was the most effective for sustained release.
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1. INTRODUCTION

1.1. GLOBAL HEALTH IMPACT OF CATARACTS
Cataracts are characterized by a cloudy opacification of the ocular lens that
progressively worsens to the point of complete vision loss. They are also the leading
cause of blindness worldwide.1 Currently, the only available treatment for patients with
cataracts is surgical removal of the cataractous lens and subsequent implantation of an
artificial lens. Although this procedure is routine and relatively safe, it is not without
drawbacks. As with any surgery, there is a risk of serious complications such as capsular
rupture, loss of vitreous, and endophthalmitis.2 In addition, artificial lenses lack several
important properties of natural lenses. The natural lens is able to stretch, allowing for
accommodation or focusing on objects or features at a variety of distances. Artificial
lenses from cataract surgery do not recapitulate this ability. Furthermore, research
conducted by Lim et al. suggests that the natural lens plays a significant role in
maintaining ocular health.3 It serves as a reservoir for the vital antioxidant glutathione
(GSH), protecting neighboring structures from oxidative damage. With this reservoir
removed, patients may be at a greater risk of developing other oxidative stress-related eye
disorders such as macular degeneration. Therefore, there is a high demand for non
invasive pharmaceutical alternatives to surgery to treat, prevent, or delay cataract
formation.

1.2. CATARACTOGENESIS AND AVENUES FOR TREATMENT
The lens contains highly ordered layers of tightly packed cells known as lens
fibers. The refractive power and transparency of the lens is attributed to water-soluble
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proteins known as crystallins which compose more than 90% of the protein content of the
lens.4, 5 Oxidative damage can disrupt the native structure of these proteins, resulting in
aggregation and loss of transparency. Thus, cataracts are attributed to the aggregation of
crystallins. The primary source of oxidative damage in cataracts is most likely ultraviolet
radiation; however, other contributing sources of oxidative stress include injury, genetic
mutation, and exposure to toxicants or ionizing radiation.
In order to maintain transparency, the nuclear portion of the lens forgoes light
scattering organelles such as nuclei, mitochondria, and endoplasmic reticula.6 As a result,
lens fiber cells are less metabolically active than most tissues, and once these cells
mature, the crystallins are not replaced. Therefore, oxidative damage to crystallin proteins
accumulates over a person’s lifetime, progressively worsening with age. It is well
documented that damage to these proteins is correlated to their aggregation.7, 8 Oxidation
of cysteine and methionine residues progressively increase with cataract severity until
>90% of cysteine residues and 50% of methionine residues are oxidized.7 Oxidation of
cysteine residues in crystallin proteins is noteworthy because it results in intra- and inter
protein cross-linking, altering the native structure of the protein, decreasing the solubility
and thus, lens transparency.
Crystallins rely heavily on endogenous antioxidants such as GSH to protect them
from oxidative damage in order to preserve their normal structure and function.3, 8 9
However, levels of these endogenous antioxidants decrease significantly with age,10, 11
leaving the lens vulnerable to oxidative insult.12, 13 Indeed, reports have shown that more
than 60% of GSH is depleted in cataractous lenses.8
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Since loss of endogenous antioxidant defenses is so strongly correlated with the
progression of age-related nuclear cataract, bolstering these defenses with exogenous
antioxidants is one of the primary treatment strategies being explored for delaying
cataract progression.
Supplementing GSH directly is impractical due to its low membrane permeability
and enzymatic degradation; however, other thiol-containing antioxidants have shown
some promise. Thiol antioxidants can scavenge ROS and undergo thiol-disulfide
exchange with oxidized cysteine residues. Indeed, reports in the literature demonstrate
that thiol antioxidants may prevent or ameliorate cataracts.14, 15
1.2.1.

Tiopronin. Tiopronin, formally known as 2-mercaptopropionyl glycine

(MPG), is an FDA-approved thiol antioxidant that is used clinically to treat cystinuria.
Patients with cystinuria have high levels of cystine in their urine, resulting in cystine
kidney stones. Tiopronin undergoes thiol-disulfide exchange with cystine to form
tiopronin-cysteine, which is more urine-soluble. This thiol-disulfide exchange, in
combination with the capacity for scavenging ROS, may be beneficial for protecting
against oxidative insults and reducing crystallin protein disulfides in the lens.
In fact, MPG has demonstrated anticataract effects in various animal and cell
models16-20 and even human cataract patients.21 Although these results are promising, the
routes of administration used are impractical for human patients. When MPG is
administered orally, very high doses are required for it to accumulate in the lens. This is
attributed to the fact that the lens lacks a direct, dedicated blood supply. Maintaining such
high doses can result in several systemic side effects.22, 23
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1.2.2. Eye Drops Are the Preferred Route of Administration. Eye drops offer
several advantages over oral and other systemic routes of administration. They are easy to
administer and allow for localized application to the target organ, circumventing the need
for high systemic doses and reducing the risk and severity of side effects. However, this
approach poses challenges as well. The eye has a number of anatomical and physiological
barriers against foreign species, and the majority of the drug is blinked away or wasted in
tears.24 The remaining drug must then penetrate the cornea and diffuse through the
aqueous humor in sufficient concentrations to reach the lens. In order to achieve effective
concentrations of MPG in the lens, it is necessary to prolong residence on the cornea.
1.2.3. Drug Delivery Vehicles Can Promote MPG Uptake and Efficacy. To
increase drug residence time and penetration, drug delivery methods such as
biocompatible polymers or gels have been explored. For example, a poloxamer gel-based
drug delivery vehicle for MPG was studied in rodents.18 The drug delivery gel increased
MPG residence time, allowing more the drug to penetrate the cornea, and thus delayed
cataract formation significantly longer compared to MPG solution. Although they have
generated a great deal of interest for ocular drug delivery,25-27 gels are not ideal agents for
this purpose due to their instability under sterilization and storage conditions.28-30 In
addition, as an antioxidant, MPG is prone to oxidation under these conditions. An ideal
delivery platform for a thiol drug like MPG would prolong its retention on the ocular
surface, augment its antioxidant properties, and protect it from premature degradation.
1.2.4. Nanodiamond Drug Delivery. Nanodiamond (ND) is a promising
candidate for drug delivery due to its biocompatibility, physical properties, and
customizability.31 Further, ND is chemically stable and does not degrade under harsh
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sterilization conditions.32 Nanodiamonds are approximately spherical particles with a
primary particle size of 4-6 nm, which results in specific surface areas in the range of
300-500 m2/g for adsorption or chemical binding of drugs.33 Moreover, the surface of
nanodiamond can be functionalized to suit a variety of applications.34 For example,
carboxylated nanodiamond (ND-COOH) can be used for the delivery of positively
charged chemotherapy drugs.35-40 The majority of the ND-COOH surface will be
negatively charged at physiological pH (7.4) due to the deprotonation of the carboxylic
acid groups. The positively charged chemotherapy drug tends to remain bound to the
negatively charged ND-COOH due to electrostatic interactions. Upon reaching the acidic
microenvironment surrounding tumor cells, however, the negative charge on the NDCOOH will become neutralized. With electrostatic interactions greatly reduced, the drug
is readily desorbed in the tumor microenvironment.
In the case of ocular drug delivery, pH-triggered release is not a primary concern.
Instead, it may be useful to engineer the nanodiamond surface to maximize interactions
with the cornea in order to improve residence time and resist being blinked away. Other
considerations include ND loading capacity, agglomeration, rate of release, toxicity
limits, and impact on drug effectiveness. Nanodiamond may also be particularly
advantageous for delivery of antioxidants because they can absorb UV light, thereby
preventing premature degradation of the antioxidant drug.41 Even better, some studies
have shown that ND may exhibit some level of intrinsic antioxidant activity.41, 42
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1.3. DEVELOPMENT AND EVALUATION OF ND:MPG FORMULATIONS
The studies reported in this dissertation reflect the foundational work necessary
for evaluating the potential for MPG to protect against oxidative stress and to establish
and evaluate the potential of ND as an MPG delivery vehicle for the prevention of
cataract and other age-related eye disorders. This dissertation reports the following three
studies in greater detail:
1. The potential of MPG to protect cells from oxidative damage was evaluated in an
epithelial cell line commonly used for early drug screening.
2. A high-sensitivity method was developed for quantifying MPG and its metabolite,
MPA, in ocular tissues. This is a necessary tool for determining the extent of
MPG loading and release from ND, as well as its fate when administered to
biological models.
3. The effect of ND surface chemistry on adsorption and release of MPG was
determined. This information is important for informing the selection of surface
functionality in the context of different applications. The results of this study can
also be used to understand why one type of ND functionalization may be more or
less effective than another.
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PAPER

I.
PROTECTIVE EFFECTS OF TIOPRONIN ON OXIDATIVELY
CHALLENGED HUMAN LUNG CARCINOMA EPITHELIAL CELLS (A549)

Justin Beltz1, Anna Chernatynskaya1, Annalise Pfaff1, Nuran Ercal1’*
1Deparment of Chemistry, Missouri University of Science and Technology, Rolla, MO
65409
1J. Beltz and A. Chernatynskaya contributed equally to this work as primary authors.
*Corresponding Author
Address: 230 Schrenk Hall, 400 West 11th Street, Rolla, MO 65409
Phone: (573) 341 6950
E-mail: nercal@mst.edu

ABSTRACT

Tiopronin (MPG) is a thiol antioxidant drug that has been explored as a treatment
for various oxidative stress-related disorders. However, many of its antioxidant
capabilities remain untested in well-validated cell models. To more thoroughly
understand the action of this promising pharmaceutical compound against acute oxidative
challenge, A549 human lung carcinoma cells were exposed to tert-butyl hydroperoxide
(tBHP) and treated with MPG. Analyses of cell viability, intracellular glutathione (GSH)
levels, and prevalence of reactive oxygen species (ROS) and mitochondrial superoxide
were used to examine the effects of MPG on tBHP-challenged cells. MPG treatment
suppressed intracellular ROS and mitochondrial superoxide and prevented tBHP-induced
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GSH depletion and apoptosis. These results indicate that MPG is effective at preserving
redox homeostasis against acute oxidative insult in A549 cells if present at sufficient
concentrations during exposure to oxidants such as tBHP. The effects of treatment
gleaned from this study can inform experimental design for future in vivo work on the
therapeutic potential of MPG.
Keywords: thiols, antioxidant, oxidative stress, reactive oxygen species (ROS),
glutathione, tiopronin

1. INTRODUCTION

#-(2-mercaptopropionyl)glycine (MPG), or tiopronin, is low-molecular-weight
thiol derivative of glycine that has been used to treat a variety of conditions. MPG was
one of the first disease-modifying anti-rheumatic drugs [1-3], but it has been superseded
by biologics and is now only applied in certain refractory cases [4,5]. MPG is the firstline treatment for cystinuria, in which it forms mixed disulfides that are up to 50 times
more soluble than cystine, thus preventing the formation of cystine kidney stones [6,7].
While these applications fill important medicinal niches, the antioxidative properties of
MPG have warranted its investigation for the treatment of more prevalent conditions. Its SH moiety can reduce disulfide linkages between oxidized biothiols, like glutathione
disulfide, restoring them to their native state [8,9]. In addition, MPG is regarded as an
effective chelator of heavy metals such as mercury and copper. In silico models predict
that formation of MPG-copper(II) complexes can reduce the rate constant of the first step
in the Haber-Weiss reaction six-fold [10]. Because of these significant antioxidant
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properties, MPG has been used to protect against chemotherapy-induced nephro- and
hepatotoxicity [11,12] , radiation poisoning [13], and ischemia-reperfusion injury to
cardiac and lung tissue [12,14]. Further, MPG may be able to counteract oxidative
processes that lead to lens opacification in senile cataracts [15-21]. MPG offers several
advantages over similar drugs, including a more favorable side effect profile than Dpenicillamine [4] and better bioavailability than ^-acetylcysteine [22,23]. Moreover,
MPG’s primary metabolite, 2-mercaptopropionic acid, is also a potent radical scavenger
[24]. With the growing impetus to repurpose pharmaceuticals, the medical community
stands to gain potential treatments and greater understanding of oxidative stress-related
conditions from renewed interest in MPG. However, its action against acute exogenous
oxidative insult in cell models has not been thoroughly characterized.
To bridge this gap in understanding, well-established cell lines such as A549 are
commonly used to study the action of drugs in vitro [25-27]. As a pulmonary epithelial
cell line, it is often employed to study effects of inhalation exposure to environmental
contaminants, in which oxidative stress plays a key role [28]. Further, it is recognized as
a useful model for early-stage biopharmaceutical research, including studies of drug
metabolism and cytotoxicity [29,30]. A well-validated oxidant is another integral
component of an appropriate system for testing an antioxidant drug. For in vitro studies,
tert-butyl hydroperoxide (tBHP) is more reliable than hydrogen peroxide, as tBHP has
demonstrated more consistent ability to induce oxidative stress than H 2O2 [31,32]. This
may be attributed to the greater stability of the tert-butoxyl radical in aqueous solution
[33] and fewer enzymes dedicated to its detoxification (e.g., glutathione peroxidase only
versus glutathione peroxidase and catalase for H2 O2) [25]. Further, decomposition of
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tBHP and downstream action of its byproducts may recapitulate many of the oxidative
mechanisms observed in vivo, including lipid peroxidation, DNA damage, depletion of
GSH and protein thiols, alteration of intracellular calcium homeostasis, and apoptosis
[25,34]. For these reasons, tBHP is better suited for probing the intracellular action of
MPG. Therefore, we utilized tBHP to rapidly induce severe oxidative damage in A549
cells and administered MPG simultaneously to test the action of MPG against acute
oxidative insult. To observe and characterize the effects of MPG under these conditions,
we examined cell viability, intracellular GSH levels, and distribution of cells in apoptotic
and non-apoptotic populations exhibiting intracellular ROS and mitochondrial
superoxide.

2. MATERIALS AND METHODS

2.1. CHEMICALS AND REAGENTS
MPG, tBHP solution, Tris-HCl, L-serine, boric acid,
diethylenetriaminepentaacetic acid, and A-(1-pyrenyl)maleimide were purchased from
MilliporeSigma (St. Louis, MO). MPG stock solutions were prepared in sterile Type 1
water prepared in-house with a Millipore Simplicity 185 System. Glacial acetic acid, ophosphoric acid, and high-performance liquid chromatography (HPLC) grade solvents
were purchased from Fisher Scientific (Fair Lawn, NJ).
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2.2. CELL CULTURE AND PRELIMINARY EXPERIMENTS
A549 (human lung carcinoma) cells were kindly provided by Dr. Yue-Wern
Huang from the Biological Sciences Department at Missouri University of Science and
Technology.
Cells were grown in phenol-red-free DMEM/F12 medium (Thermo Fisher
Scientific, Waltham, MA) supplemented with 10% heat-inactivated fetal bovine serum
(FBS) and 1% penicillin/streptomycin/amphotericin B (Thermo Fisher Scientific) in a
humidified incubator with 5% CO2/95% air at 37°C. Serum- and growth-factor-free
medium was used for all MPG and tBHP experiments, instead of the fully supplemented
media described above. Cells were passaged twice per week at a subcultivation ratio of
1:3. All experiments were performed using cells between passage 10 and 30.
To determine an appropriate concentration of tBHP for use in this study, A549
cells were seeded in multiple-well plates and divided into groups. Each group was
incubated for 3 hours with a different concentration of tBHP in serum-free media,
ranging from 0.25 mM to 4.0 mM. Cytotoxicity of tBHP in each group was assessed via
MTT assay as described below to identify the range of concentrations at which cell
viability was reduced to 50-60% of the control, which was shown to be 0.5 to 1.0 mM.
To determine whether cells received sufficient oxidative insult, intracellular GSH levels
were measured in groups treated with tBHP concentrations ranging from 0.4 to 0.8 mM
for 3 hours. Based on these preliminary experiments, a concentration of 0.6 mM tBHP
was selected for use in the remaining experiments.
Next, an appropriate concentration of MPG for treating tBHP-exposed cells was
selected. To determine whether MPG alone had any adverse effect on cell viability,
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A549 cells were seeded in multiple-well plates and divided into groups. Each group was
incubated for 3 hours with different concentrations of MPG in serum-free media, ranging
from 0.08 mM to 10 mM, and MPG was not found to significantly affect cell viability at
these concentrations (data not shown). To determine an appropriate concentration for use
in tBHP-exposed cells, a similar experiment was conducted with the simultaneous
addition of 0.6 mM tBHP and either 1.0, 1.5, 2.5, or 5.0 mM MPG for 3 hours. Cell
viability and GSH levels in respective groups indicated that 5.0 mM MPG provided
optimal protection against tBHP. Based on these preliminary experiments, 5.0 mM MPG
and 0.6 mM tBHP were used in subsequent experiments to determine the effects of MPG
on oxidative stress induced by tBHP.

2.3. EXPERIMENTAL DESIGN
The A549 cells were grown in complete media and allowed to proliferate for 24
hours. The cells were divided into 4 treatment groups: control, MPG only, tBHP only,
and MPG + tBHP. After the 24-hour proliferation time, the complete medium was
removed and replaced with the treatment medium associated with the corresponding
treatment group (Table 1). The treatment media were supplemented with tBHP or MPG
immediately prior to each experiment from freshly prepared concentrated stock solutions.
The cells were allowed to incubate in the treatment media for 3 hours. After this time, the
treatment media were removed. Cell viability and oxidative stress parameters including
GSH and flow cytometric analysis of ROS and mitochondrial superoxide were
determined after treatment as described in the following sections.
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Table 1. Treatment media compositions
Group
Control
M PG only
tBHP only
M PG + tBHP

Treatm en t m edium
M edium
M edium + 5 mM MPG
M edium + 0.6 mM tBHP
M edium + 5 mM M PG + 0.6 mM tBHP

2.4. CELL VIABILITY
Cells were seeded at a density of 2 x 104 cells/well in 96-well plates and allowed
to adhere and proliferate for 24 hours. Then, cells were divided into groups and treated as
described in the experimental design. After the treatment, the treatment media were
replaced with fresh F12 medium, and cell viability was determined using the Vybrant
MTT Cell Proliferation Assay Kit (Invitrogen, Carlsbad, CA) as described by the
manufacture. The MTT assay is a colorimetric assay through which cell viability is
estimated by conversion of the water soluble MTT (3-(4,5-dimethylthiazol-2-yl)-2,5dimethyltetrazolium bromide) to an insoluble formazan by viable cells. The formazan is
then solubilized by sodium dodecyl sulfate (SDS), and the concentration is determined by
measuring absorbance at 570 nm using a microplate reader (Fluor Star Optima, BMG,
Labtech). Cell viability was expressed as the absorbance by the contents of a given well
divided by that of the mean absorbance measured for the control group.

2.5. QUANTIFICATION OF INTRACELLULAR GSH LEVEL
Cells were seeded at a density of 6 x 105 cells/well in 6-well plates 24 hours
before the experimental treatment. Cells were treated as described in the experimental
design. Following treatment, the cells were harvested with trypsin/EDTA and collected in
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1.5 mL RINO tubes (Next Advance, Troy, NY, USA). The cell suspensions were
centrifuged at 500 x g for 10 min at 4°C. The supernatants were removed, and the cells
were resuspended in 1 mL aliquots of PBS to rinse away remaining media and
extracellular GSH. This centrifugation and rinsing process was repeated. After rinsing,
the cells were centrifuged again at 500 x g and resuspended in 250 pL aliquots of chilled
serine-borate buffer (100 mM Tris-HCl, 5 mM L-serine, 10 mM boric acid, 1 mM
diethylenetriaminepentaacetic acid, pH 7.0). A 100 pL scoop was used to add about 100
pL of zirconium oxide beads (0.5 mm diameter, Next Advance) to each of the cell
suspensions. The cells were homogenized using a Bullet Blender Storm tissue
homogenizer (Next Advance) at speed “8” for 3 min. After homogenization, the cells
were immediately centrifuged at 5000 x g for 5 min at 4°C. Then, 100 pL aliquots of
supernatant were collected from each RINO tube for analysis of GSH and total protein
content.
Intracellular GSH levels were determined by HPLC with pre-column
derivatization and fluorescence detection, according to a method developed in our
laboratory [35]. Briefly, 50-pL aliquots of cell homogenate were diluted with 200 pL of
serine-borate buffer. The samples were derivatized by the addition of 750 pL of N-(1pyrenyl)maleimide (1 mM in acetonitrile). The samples were mixed and allowed to react
for 5 min. After this time, 10 pL of 2 M HCl were added to stabilize the fluorescent
adducts. Samples were filtered with 0.45 pm nylon membrane filters. Samples were
injected onto an Orochem (Naperville, IL, USA) Reliasil ODS-1 column (4.6 mm i.d. x
250 mm) and eluted with a mobile phase consisting of 70:30 (v/v) acetonitrile-water with
1 mL/L of o-phosphoric acid and 1 mL/L of glacial acetic acid, delivered at a flow rate of
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1 mL/min. GSH levels were determined by using a calibration curve prepared from
standards processed in parallel with the unknown samples.
The GSH levels were normalized to the amount of total protein present in each
sample. Total protein levels were estimated using the Coomassie dye-binding method
described by Bradford [36]. Bradford dye reagent (Bio-Rad, Hercules, CA, USA) was
diluted five-fold in serine borate buffer, and 1 mL aliquots of the diluted dye reagent
were added to 20 pL of diluted cell homogenate in cuvettes. The samples were left to
incubate at room temperature for at least 5 min. The absorbance of 595 nm light was
correlated to the total protein concentration using a calibration curve. Albumin from
bovine serum was used to make calibration standards to estimate the protein content in
the cell homogenates.
To account for differences in live cell populations between treatment groups,
GSH levels were reported in nanomoles of GSH per milligram of protein (nmol/mg).

2.6. FLOW CYTOMETRY ANALYSIS OF APOPTOTIC CELLS AND
INTRACELLULAR ROS MEASUREMENT
Intracellular ROS content was measured using the carboxy derivative of
fluorescein, carboxy-HsDCFDA (6-carboxy-2’,7’-dichlorofluorescein diacetate,
Molecular Probes, Invitrogen), due to its additional negative charges that enhance cellular
retention [37]. Flow cytometry (BD Accuri C6, BD Biosciences, Ann Arbor, MI) was
used to assess the distribution of cells that contained ROS (ROS+ cells) within apoptotic
and non-apoptotic cell populations. Cells were seeded on 24-well plates (Corning) at a
density of 2 x 105 cells/well, grown over 24 hours, divided into groups and dosed as
described previously. Trypsinized cells were washed with PBS and re-suspended in 250
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gL of PBS containing 10 gM carboxy-H^DCFDA. After incubation for 30 minutes at
37°C, the cells were washed with annexin V binding buffer and stained with 7-AAD (7aminoactinomycin D, BD Pharmingen) and Annexin V Alexa Fluor 647 Conjugate
(Invitrogen) for 15 minutes at room temperature in the dark. The FL-1 channel (Xex = 488
nm and Xem= 533 nm) was used for carboxy-H2DCFDA, and the FL-3 channel (Xex = 533
nm and Xem= 670 nm) was used for 7-AAD. Annexin V Alexa Fluor 647 fluorescence
was measured using the FL-4 channel (Xex = 640 nm and Xem= 675 nm). Debris were
excluded by forward vs. side scatter gating. Results are reported as percent of total cell
population.

2.7. FLOW CYTOMETRY DETERMINATION OF MITOCHONDRIAL
SUPEROXIDE
MitoSOX Red mitochondrial superoxide indicator (MSR) is a fluorogenic dye for
selective detection of superoxide in mitochondria of live cells (Molecular Probes,
Eugene, OR). MSR is a dihydroethidium dye with a lipophilic, positively-charged sidechain for targeted absorption by the mitochondria. Upon oxidation by superoxide, the dye
exhibits red fluorescence [38]. For analysis of superoxide generated in mitochondria,
cells were grown in the same conditions as for the measurement of ROS content via flow
cytometer. Harvested cells were washed with PBS and re-suspended in 250 gL of PBS
containing 5 gM MSR. Cells were incubated for 30 minutes at 37°C. After incubation
with MSR, LIVE/DEAD Fixable Green Dye (Molecular Probes, Eugene, OR) was added
directly to each sample according to the manufacture’s recommendation. Cells were
incubated for an additional 15 minutes at room temperature. The final stain, Annexin V
Alexa Fluor 647 Conjugate, was added after washing cells with annexin V buffer. Cells
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were analyzed by flow cytometry using the FL-1 channel (kex = 488 nm and Xem= 533
nm) for LIVE/DEAD Fixable Green, the FL-2 channel for MSR (kex = 488 nm and kem =
585 nm), and the FL-4 channel for Annexin-V Alexa Fluor 647 (kex = 640 nm and kex =
675 nm). Results are reported as percent of total cell population with MSR fluorescence
(MSR+) cells in apoptotic and viable populations in each treatment group. Debris were
excluded by forward vs. side scatter gating.

2.8. STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism 8 software (GraphPad,
San Diego, CA, USA). All values were reported as mean ± standard deviation of at least
three separate experiments, with n = 3-16. Statistical significance was performed by two
way analysis of variance (ANOVA) for flow cytometry experiments and one-way
ANOVA for all other experiments. ANOVA was followed by Tukey’s or Dunnette’s
multiple comparison tests.

3. RESULTS AND DISCUSSION

3.1. SELECTION OF DOSING CONCENTRATIONS
To determine an appropriate concentration of tBHP for inducing oxidative stress,
cell viability and GSH levels were determined following exposure to varied
concentrations of tBHP. GSH, y-glutamyl-cysteinyl-glycine, is the most abundant non
protein thiol in the body and an essential endogenous antioxidant. It plays a vital role in
reduction and detoxification of ROS, including peroxides like tBHP and is therefore
crucial to the maintenance of redox homeostasis. Increase in oxidants can upset this
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delicate balance, leading to the oxidative modification of critical cellular components,
dysfunction, and ultimately apoptosis. The effects of increasing fBHP concentrations on
cell viability and GSH levels are reported in Figure 1. Concentrations from 0.25 mM to
4.0 mM significantly decreased cell viability in a dose-dependent manner. The effect of
tBHP concentration on GSH levels and cell morphology were also considered for
selection of an appropriate concentration of fBHP for subsequent experiments. tBHP
concentrations from 0.4 mM to 0.8 mM resulted in a statistically significant decrease in
levels of intracellular GSH, which correlates with the dose-dependent decrease in cell
viability.

Figure 1. A. Plot of cell viability vs. fBHP concentration. The height of the columns
indicates the mean viability from 9 experiments. Error bars indicate standard deviation.
B. Plot of intracellular GSH concentration vs. fBHP concentration. The height of the
columns represents the mean of 3 experiments. Error bars indicate standard deviation.
****p < 0.0001 compared to control. ***p < 0.001 compared to control. *p < 0.05
compared to control.

Upon comparing the effects of tBHP on GSH levels and cell morphology, it was
noted that at 0.6 mM fBHP, GSH had decreased by approximately 50%, but at 0.8 mM,
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cells lost adhesion, which interfered with analysis and weakened integrity of the model
overall. A tBHP concentration of 0.6 mM struck the best balance between oxidative
damage and maintenance of normal cell morphology. Therefore, 0.6 mM tBHP was
selected for subsequent experiments. Although this tBHP concentration is relatively high,
the A549 cell line is reportedly resistant to oxidative insult [39].
In the next set of experiments, a variety of MPG concentrations from 1.0 to 5.0
mM were tested in different groups to determine the appropriate concentration for
protection against oxidative stress induced by 0.6 mM tBHP. Intracellular GSH levels
were used to assess the effectiveness of each dose, and the results are shown in Figure 2.

500

MPG + tBHP

Figure 2. Plot of intracellular GSH concentration vs. dosing concentration of MPG. The
height of the columns represents the mean of 3 experiments. Error bars indicate standard
deviation. ****p < 0.0001 compared to tBHP only. **p < 0.01 compared to tBHP only.

Concentrations ranging from 1.0 mM to 5.0 mM MPG afforded significant
improvement in GSH levels compared to untreated, tBHP-exposed cells, but cells treated
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with 5.0 mM MPG exhibited the highest GSH levels. Since preliminary experiments
showed concentrations of MPG up to 10 mM to be nontoxic to A549 cells, treatment with
5.0 mM MPG was deemed an appropriate treatment for tBHP-induced oxidative stress
for the remainder of the study.

3.2. EFFECT OF MPG ON INTRACELLULAR GSH IN OXIDATIVELY
CHALLENGED A549 CELLS
To confirm the effects of 5.0 mM MPG on intracellular GSH levels in A549 cells,
the cells were divided into groups as discussed in the experimental design and seeded as
described earlier. The results of the intracellular GSH analyses are reported in Figure
3A.The data were normalized by the amount of protein present in each sample to account
for differences in viable cell count. Exposure to tBHP without MPG resulted in a
significant decrease in intracellular GSH levels compared to the control group. Cells
treated with MPG, either with or without tBHP, had GSH levels that were not
significantly different from that of the control group. Therefore, administration of 5.0
mM MPG with 0.6 mM tBHP was effective for preventing loss of free GSH, and MPG
alone does not increase GSH levels beyond that of the control group. These results are
consistent with the hypothesis that GSH levels are spared by the action of MPG as
opposed to being directly increased.

3.3. EFFECT OF MPG ON VIABILITY OF OXIDATIVELY CHALLENGED
A549 CELLS
To determine whether MPG could protect cells from tBHP-induced loss of
viability, the MTT assay was used as an indicator of cellular metabolism. This assay is
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based on the ability of metabolically active cells to reduce MTT to an insoluble, colored
formazan product that can be measured spectrophotometrically. Cell viability for each
treatment group is reported in Figure 3B as a percentage of absorbance at 570 nm
compared to that of the control group. As was the case in our preliminary studies, cells
exposed to 0.6 mM fBHP without MPG exhibited significantly less viability compared to
the cells in the control group, and the viability of cells in the MPG + tBHP group was
statistically similar to that of the cells in the control group. Treatment of A549 with 5
mM MPG alone also did not increase or decrease cell viability.

Figure 3. A. Plot of treatment vs. intracellular GSH concentration. The height of the
columns indicates the mean of 9 experiments and error bars represent the standard
deviation. B. Plot of treatment vs. cell viability. The height of the columns indicates the
mean of 14 experiments, and error bars represent the standard deviation. ****p < 0.0001
compared to control.

This trend closely parallels that of intracellular GSH levels and makes sense in the
context of the biochemistry behind the MTT assay. The reduction of MTT to formazan is
sensitive to decreases in available NADPH [40]. The NADPH cofactor serves as the
reductant for a host of anabolic processes, as well as the reduction of oxidized glutathione
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to its active reduced form. Thus, gross metabolic dysfunction resulting from tBHP is
manifested in the inability of oxidatively damaged, dying cells to reduce MTT and
regenerate GSH from its oxidized form. In contrast, cells treated with MPG exhibited
marked improvement in both cell viability and GSH levels. We hypothesize that this is
due to the following effects of MPG. As a thiol antioxidant that can directly reduce
tBHP-derived ROS, MPG can spare GSH from oxidation, leaving cellular GSH stores
largely intact. In preventing oxidation of GSH, MPG also preserves NADPH for use in
reductive biosynthesis and conversion of MTT to formazan.

3.4. EFFECT OF TREATMENT ON APOPTOTIC AND NECROTIC CELL
POPULATIONS
Flow cytometry is a well-established technology that has been widely used for
measuring intrinsic and extrinsic properties of fluorescently labeled cells. This property
permits the identification of subpopulations within the sample, and quantification of cell
populations through selective fluorescence labeling. While microplate readers provide
rapid data acquisition, the accuracy of the measurements suffers since the end value
corresponds to the average fluorescence per well while flow cytometry provides
information at the single-cell level. For this analysis, cells were labeled with 7-AAD and
Annexin V Alexa 647 to investigate live, necrotic, and apoptotic cell populations. Live
cells are not typically permeable to 7-AAD. Cells in early apoptotic stages bind only to
Annexin V Alexa 647, while cells in late apoptotic stages bind to both Annexin V Alexa
647 and 7-AAD. Necrotic cells bind to 7-AAD, but not Annexin V Alexa 647.

23

Representative dot-plots from the flow cytometry analysis are provided in Figure
4. The mean distributions of cells among apoptotic, necrotic, and viable cell populations
from 8 replicate experiments are summarized in Table 2.
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Figure 4. Representative dot-plots from flow cytometry analysis of apoptotic cells.
Shown are plots of fluorescence associated with Annexin V Alexa 647 (FL-4) vs. 7-AAD
(FL-3) from different treatment groups.

Table 2. Effects of exposure to tBHP and treatment with MPG on viable, apoptotic, and
necrotic subpopulations.
Subpopulation
Early apoptotic
Late apoptotic
Viable
Necrotic

Cells in subpopulation (% of total cell population)t
Control
tBHP only MPG + tBHP
MPG only
3.1 ± 1.3
2.6 ± 0.9
4.3 ± 1.3
3.0 ± 0.7
2.3 ± 0.4****
2.3 ± 0.6****
11.2 ± 4.7 2.9 ± 0.7****
94.3 ± 1.2****
94.5 ± 0.8****
81.7 ± 8.2 93.5 ± 1.0****
0.4 ± 0.3
0.6 ± 0.4
2.8 ± 2.6
0.6 ± 0.6

t Mean ± SD of 8 experiments.
**** p < 0.0001, compared to tBHP only group.
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As observed previously, the percentage of viable cells in the MPG + tBHP treated
group was significantly higher than in the tBHP group. Further, the percentage of viable
cells in the MPG + tBHP group was statistically similar to the percentages in the MPG
only group and the control group. The same trend was observed within late apoptotic
subpopulations. Exposure to 0.6 mM tBHP without MPG resulted in an elevated
proportion of cells exhibiting fluoresence associated with binding of 7-AAD and Annexin
V Alexa 647. However, cells treated with MPG, alone or with tBHP, were not
significantly different from the control cells. These data suggest that exposure to 0.6 mM
tBHP without MPG results in oxidative stress-associated apoptosis while treatment with
MPG mitigates the damage that triggers this process. Although there does not appear to
be a significant difference in the proportion of cells occupying the necrotic quadrant
among groups, this can be attributed to the fact that cellular debris are excluded prior to
quantitation. There was a significantly lower number of cells available for counting in the
tBHP only group, compared to the other groups. This loss of countable cells is indicative
of membrane disintegration associated with tBHP exposure.

3.5. DISTRIBUTION OF CELLS WITH ROS PRESENT IN APOPTOTIC AND
NON-APTOPTOTIC SUBPOPULATIONS
Based on the results of GSH and MTT assays, we hypothesized that MPG
prevents cell death by protecting cells from oxidative damage, and therefore, we would
expect to see significantly higher levels of ROS in cells in the tBHP only group than in
the other groups. To estimate the levels of intracellular ROS, carboxy-HsDCFDA was
used to identify ROS+ cells. Carboxy-HsDCFDA is a membrane-permeable derivative of
the fluorescent probe fluorescein. Upon cleavage of its acetate groups and oxidation by
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intracellular ROS, the dye becomes trapped within the cell and fluoresces green [38].
Cells were co-stained with two other fluorescent probes, Annexin V Alexa Fluor 647
conjugate and 7-AAD, and then the cells were subjected to flow cytometric analysis.
Representative dot plots are shown in Figure 5. In this study, co-staining was used to
differentiate between apoptotic and non-apoptotic cell subpopulations and to exclude
necrotic cells since membrane leakage makes estimation of intracellular ROS unreliable.
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Figure 5. Representative dot-plots from flow cytometry analysis of ROS in apoptotic and
live subpopulations. The cells were gated excluding debris. Viable cells were gated by
exclusion of 7-AAD+ cells (FL-3) on 2D plots (live gate). The quantification of ROS was
done using 2D plots of Carboxy-H^DCFDA (FL-1) vs. Annexin V Alexa 647 (FL-4).
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Table 3. Effects of tBHP exposure and MPG treatment on percentage of ROS+ cells in
apoptotic and live cell populations.
Subpopulation
ROS in apoptotic cells
ROS in live cells
Total ROS

Cells in subpopulation (% of total cell population)*
Control
tBHP only MPG + tBHP
MPG only
1.7 ± 0.9
1.3 ± 0.8
3.6 ± 1.4
1.6 ± 0.6
2
2
+
1
1
****
1.5 ± 0.5****
22.5 ± 2.3 4.2 ± 1.0****
3.5 ± 1.6****
3.3 ± 0.9****
26.1 ± 2.7 5.8 ± 1.1****

t Mean ± SD of 8 experiments.
**** p < 0.0001, compared to tBHP only group.

The results of the analysis (summarized in Table 3) indicate that there were
indeed significantly more ROS detected in live cells treated with tBHP only than in any
of the other groups. This correlates well with the GSH and cell viability results and is
consistent with the supposition that MPG protects cells from oxidative stress by reducing
ROS associated with exposure to tBHP.
Numbers of ROS+ cells in apoptotic subpopulations were low in all groups, and
differences between these subpopulations did not reach statistical significance. Small
subpopulations of apoptotic, ROS+ cells may be due to the exclusion of late-stage
apoptotic and necrotic cells by gating out 7-AAD-fluorescent cells. As shown in Table 2,
the tBHP only group had a significantly higher subpopulation of late-stage apoptotic
cells, suggesting that tBHP-induces rapid progression to late-stage apoptosis or secondary
necrosis [41]. Since these cells exhibit 7-AAD fluorescence, they would have been gated
out and thereby excluded from the study [42].

3.6. DISTRIBUTION OF SUPEROXIDE PRESENT IN MITOCHONDRIA OF
APOPTOTIC AND NON-APOPTOTIC POPULATIONS
Low levels of superoxide in mitochondria are generated as a result of normal
metabolic processes, but excessive amounts are associated with electron-transport chain
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dysfunction [43]. This can lead to decreased ATP production, loss of mitochondrial
membrane potential, and ultimately opening of the mitochondrial permeability transition
pore and initiation of the apoptotic cascade [44,45]. In this way, mitochondria are highly
sensitive to fluctuations in redox status, [44] and may serve as a predictor of apoptotic
response to acute oxidative insult [45].
MSR, a mitochondria-permeable dye, fluoresces upon oxidation by superoxide.
Similar to the flow cytometric analysis of ROS+ cells, MSR was used to determine the
percentage of cells with superoxide present in the mitochondria. Representative dot plots
are shown in Figure 6.

Figure 6. Representative dot-plots of from flow cytometry analysis of superoxide in
mitochondria. The total cells were gated excluding debris. Viable cells were gated by
exclusion of Live/Dead green+ cells (FL-1) on 2D plots (live gate). The quantification of
MSR+ cells was done using 2D plots of MSR (FL-2) vs. Annexin V Alexa 647 (FL-4).
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Table 4 shows the quantitative results as mean percentages of the total cell
population. The percentage of MSR+ live cells in the MPG + tBHP group was
significantly decreased compared to that in the tBHP only group. This indicates that MPG
was able to preserve mitochondrial redox status. In light of the cell viability and GSH
results, it may be the case that MPG prevents downstream release of mitochondriaderived ROS into the cell and halts progression towards apoptosis.

Table 4. Effects of exposure to tBHP and MPG on the percentage of MSR+ cells in
apoptotic and live cell populations.
Su b p o p u latio n
M SR+ in ap o p to tic cells

Cells in su b p o p u latio n (% o f to tal cell p o p u la tio n ^
Control

M PG o nly

tB H P o nly

M PG + tB H P

2.1 ± 0.5

2.0 ± 0.4

3.9 ± 1.3

2.3 ± 0.5

M SR+ in live cells

1.2 ± 0.4****

1.3 ± 0.3****

24.3 ± 3.2

8 .6 ± 1 .9 ****

To tal M SR+ cells

3.2 ± 0.8****

3.5 ± 0.5****

28.2 ± 3.5

10.9 ± 2.2****

t Mean ± SD of 8 experiments.
**** p < 0.0001, compared to tBHP only group.

4. CONCLUSIONS

In this study, tBHP was used to induce oxidative stress in A549 cells. Cells
exposed to 0.6 mM tBHP without MPG showed elevated levels of intracellular ROS,
mitochondrial superoxide, and cell death while also showing reduced levels of the vital
antioxidant GSH and reduced cell viability. When 5.0 mM MPG was present along with
0.6 mM tBHP, normal levels of these oxidative stress parameters were maintained. It is
likely that MPG is interacting as a direct ROS scavenger, and the results obtained through
this study suggest that if MPG is present in sufficiently high concentrations during an
oxidative insult, it can be highly effective at preventing the ensuing damage. It is
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probable that the MPG reacts directly with tBHP in the treatment medium, reducing it
and its oxidative byproducts before they can cause significant damage to the cells. This
action is desirable for treatment applications which demand protection against acute
oxidative insult such as radioprotection, but it is important to consider the dosing
conditions and timing since biological systems are inherently dynamic. This in vitro
system lacks many of the complexities of in vivo models and is therefore subject to some
limitations. Due to the robust nature of this lung carcinoma cell line, a relatively high
dose of tBHP was required to model acute oxidative stress. Despite the popularity of this
approach, it may not directly translate to in vivo systems. Thus, the results of this study
warrant further investigation in more representative models, such as primary cell cultures
and eventually animal studies.
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ABSTRACT

Tiopronin, formally 2-mercaptopropionylglycine (MPG), is currently prescribed
to treat cystinuria and rheumatoid arthritis, and its antioxidant properties have led to its
investigation as a treatment for cataracts, a condition in which oxidative stress is strongly
implicated. To study its accumulation in the eye, a reliable, isocratic HPLC method was
developed for the determination of MPG and its primary metabolite 2-mercaptopropionic
acid (MPA) in plasma and relevant ocular tissues. This method utilizes pre-column
derivatization and fluorescence detection. The 3.5 min separation enables highthroughput analysis, and validation experiments demonstrated that this method is suitable
for evaluating ocular accumulation of MPG and MPA at concentrations as low as 66 and
33 nM, respectively. Excellent linearity was achieved over the working concentration
range with R2 > 0.997. Extraction recovery was reproducible within each matrix and
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exceeded 97%. Accuracy was within 13.3% relative error, and intra- and inter-day
precisions were within 6% CV and 7% CV, respectively. Sample stability was
demonstrated under various storage conditions, and the use of an internal standard
conferred exceptional ruggedness. This method has been successfully applied for the
determination of MPG and MPA in plasma, cornea, lens and retina following
intraperitoneal administration of the drug in Wistar rats.

1. INTRODUCTION

MPG is a small-molecular weight synthetic aminothiol. It is also known by the
generic name tiopronin. It is primarily used to treat cystinuria and rheumatoid
arthritis.(Carlsson, Denneberg, Emanuelsson, Kagedal, & Lindgren, 1993) Its thiol
moiety confers antioxidant properties such as the ability to scavenge free radicals
(Castaneda-Arriaga, Vivier-Bunge, & Raul Alvarez-Idaboy, 2016) and undergo thiol
disulfide exchange.(Lindell, Denneberg, & Jeppsson, 1995) It has also been investigated
as a potential treatment for cataracts, (Ichikawa et al., 1980; Jiang, Sun, Shen, Wang, &
Wang, 2009) in which oxidative stress has been strongly implicated.(Lou & Dickerson,
1992; Truscott, 2005)
Although oral administration of MPG is most commonly used for cystinuria or
rheumatoid arthritis patients (Carlsson et al., 1993), it is not an effective route for
achieving appreciable concentrations of the drug in ocular tissues, especially the lens
which lacks dedicated vasculature. Local, topical administration in the form of eye drops
may allow for greater accumulation of the drug at its proposed site of action with lower
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dosages and fewer side-effects, but only if sufficient concentrations can be achieved in
the surrounding tissues to allow for diffusion or transport into the lens.Jarvinen,
Jarvinen, & Urtti, 1995) Unfortunately, rapid elimination in tear fluid and numerous
anatomical barriers prevent accumulation of MPG in the lens when instilled as eye drops.
Drug delivery vehicles may be able to overcome this obstacle, (Abdelkader, Alany, &
Pierscionek, 2015; Jiang et al., 2009) but evaluating their efficacy for this application
poses several key challenges. As shown in Figure 1, MPG is quickly metabolized to 2mercaptopropionic acid (MPA) in plasma.(Hercelin et al., 1992)

In addition, preliminary experiments in our lab suggest that MPA itself is a potent
antioxidant, and simply measuring ocular tissue levels of MPG alone provides an
incomplete picture of its fate and distribution after administration. An ideal method
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would be able to simultaneously determine levels of MPG and its major metabolite,
MPA.(Hercelin et al., 1992) In addition, a highly sensitive and specific method is
necessary when working with very limited sample quantities and highly complex
biological matrices such as rodent cornea or retina (Dalle-Donne & Rossi, 2009).
If the method is to be used for such analyses, validation in the matrices of interest
is also important. In this case, the cornea, lens, and retina are of primary interest. The
cornea is the foremost obstacle to ocular drug penetration, and understanding the drug’s
interaction with this tissue may provide key insights for improving its ability to mediate
effects in more posterior structures such as the lens.(Jarvinen et al., 1995) As cataracts
are the result of oxidative damage to crystallin proteins in the lens, this tissue is the
proposed primary site of action for MPG. Additionally, the lens serves as an antioxidant
reservoir, (Lim, Umapathy, Grey, Vaghefi, & Donaldson, 2017) and applying MPG may
help to restore redox balance, thereby inhibiting processes leading to opacification. The
retina is highly metabolically active and therefore sensitive to disruptions to ocular redox
balance. In addition, its proximity to the ocular blood supply can provide additional
information regarding influx and elimination of MPG and MPA. Finally, because a large
proportion of any drug instilled in eye drop form is eliminated by tear fluid and passes
into the bloodstream, (Jarvinen et al., 1995) plasma levels of MPG and MPA are also of
interest for understanding the ocular uptake of this drug. Finally, practical considerations
such as ease of implementation and sample processing should be taken into consideration
for experiments involving time-sensitive materials, such as biological tissues and drugs
with labile thiol functional groups. In these cases, robust methods that offer rapid and
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convenient quantification of drug concentration are preferred for high-throughput routine
analyses.(McMenamin, Himmelfarb, & Nolin, 2009)
Other methods exist for determination of MPG in tissues.(Dalle-Donne & Rossi,
2009) While most methods employ HPLC separation, detection methods vary. Some rely
on UV detection, which can suffer from limited sensitivity and interference in complex
matrices. Others employ mass spectrometric detection, which may not be accessible or
practical in many cases. Fluorescence detection, on the other hand, is both highly
sensitive and economical, making it the most popular method for detection of thiol
compounds. (McMenamin et al., 2009) Indeed, our group has previously demonstrated
successful quantification of biologically relevant thiols, including MPG, via
derivatization with maleimide dyes and HPLC separation of the fluorescent adducts.
(Penugonda, Wu, Mare, & Ercal, 2004; Ridnour, Winters, Ercal, & Spitz, 1999; Wu,
Goldstein, Adams, Matthews, & Ercal, 2006) However, the method described here offers
several significant improvements in terms of robustness, convenience, precision,
accuracy, and analysis time. It also eliminates critical matrix interferences from lens
samples which were not validated in the previous technique. It entails an isocratic RPHPLC separation following pre-column derivatization of free thiols with ThioGlo-3, a
maleimide-based fluorogenic probe (see Figure 2). Prior to derivatization, reduction with
tris(2-carboxyethyl)phosphine (TCEP) and addition of an internal standard minimize
effects of thiol oxidation during processing. The following validation studies demonstrate
that this method can accurately and reliably quantify both MPG and its major metabolite
MPA in ocular tissues and plasma at nanomolar concentrations.
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Figure 2. Derivatization of thiols with ThioGlo-3.

2. EXPERIMENTAL METHODS

2.1. CHEMICALS AND REAGENTS
MPG, MPA, N-acetylcysteine (NAC), TCEP, Tris-HCl, L-serine, and
diethylenetriaminepentaacetic acid (DETAPAC) were all purchased from MilliporeSigma
(St. Louis, MO, USA). Type I water was obtained using a Millipore Simplicity 185 water
purification system. ThioGlo-3 was purchased from Covalent Associates, Inc.
(Bellingham, WA, USA). All other reagents were purchased from Fisher Scientific
(Pittsburgh, PA, USA). was adjusted to pH 7.4 with NaOH. All other reagents were
purchased from Fisher Scientific. The injection vehicle for the animal study was a
phosphate buffered saline (pH 7.4) consisting of 137 mM NaCl, 2.7 mM KCl, 8 mM
Na2HPO4 , and 1.5 mM KH2PO4 . Serine borate buffer (SBB) consisting of 100 mM TrisHCl, 5 mM L-serine, 10 mM H3BO3 , and 1 mM DETAPAC was prepared in type 1 water
and adjusted to pH 7.0 with NaOH.
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2.2. ANIMALS
All animal procedures were approved by the Missouri University of Science and
Technology Animal Care and Use Committee. A litter of male Wistar rats weighing 12
18 g were purchased from Charles River Laboratories (Wilmington, MA, USA). All
animals were housed in a temperature-controlled room with a 12 h light-dark cycle. The
rats were fed and watered ad libitum with Purina rat chow and municipal tap water. Six
rats were fasted overnight prior to receiving an intraperitoneal injection of either MPG
(250 mg/kg body weight) or vehicle alone. Forty minutes after receiving the injection, the
animals were anesthetized, and blood was collected into heparin-coated Vacutainers (BD,
Franklin Lakes, NJ, USA) via intracardiac puncture. The animals were euthanized and
the whole eyes were immediately removed and carefully dissected in isotonic PBS to
obtain the corneas, lenses, and retinas. Plasma was collected after centrifugation of whole
blood samples at 2000 x g. All samples were stored in a freezer at -80°C until analysis.

2.3. SAMPLE PREPARATION
Corneas, lenses, and retinas were thawed and transferred to microcentrifuge tubes
containing 500 pL of ice-cold SBB, spiked with 2.5 pM internal standard (NAC) and 75
pM TCEP. The tissues were sheared in this buffer on ice using a Tissue-Tearor (BioSpec
Products, Inc., Bartlesville, OK, USA). The samples were removed from ice and allowed
to stand for 30 min for temperature equilibration and reduction of disulfide bonds. Matrix
protein content was determined via the Coomassie dye-binding method described by
Bradford. (Bradford, 1976) Briefly, Bradford dye reagent (Bio-Rad, Hercules, CA, USA)
was diluted five-fold in SBB, and 2.5 pL of the working reagent was added to 50 pL of
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tissue homogenate. The absorbance at 595 nm was recorded after 5 min. Aliquots from
lens and retina homogenates were diluted 15-fold and 2-fold, respectively to keep protein
levels within the working linear range for the Bradford assay. The homogenates were
then centrifuged for 5 min at 11,000 x g. For derivatization, 100 pL of the supernatant
solutions were transferred to tubes containing 25 pL of SBB and 375 pL of ThioGlo-3
(33 pM in HPLC-grade acetonitrile). After 20 min, samples were acidified with 5 pL of 2
N HCl, and then diluted with 250 pL of mobile phase component A.
Plasma samples were thawed, and 40-pL aliquots of plasma were diluted with 160 pL of
SBB spiked with 2.5 pM internal standard and 75 pM TCEP, and allowed to stand for 30
min. The diluted plasma samples were then centrifuged for 5 min. at 11,0000 x g. Then,
125 pL of the supernatant solutions were transferred to tubes containing 375 pL of 33pM ThioGlo-3. After 20 min, samples were acidified with 5 pL of 2 N HCl, and then
diluted with 250 pL of mobile phase component A.
The samples were filtered into sampler vials using 0.2-pm nylon syringe filters (Fisher
Scientific).

2.4. PREPARATION OF CALIBRATION STANDARDS
Calibration standards were prepared by spiking 25 pL of working solutions of
MPG and MPA into 100 pL of pooled drug-free samples of the corresponding matrix,
diluted in SBB spiked with internal standard and TCEP. The final concentrations of NAC
and TCEP all of the calibration standards were 331 nM and 9.93 pM, respectively.
Calibration standards were prepared at 9 levels over the range of 66.2 - 1656 nM for
MPG and 33.1 - 828 nM for MPA.
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2.5. HPLC PARAMETERS
A Thermo Scientific Dionex UltiMate 3000 Series HPLC system equipped with a
Dionex LPG-3400-SD pump, a Dionex ACC-3000 autosampler, and a Dionex FLD-3100
fluorescence detector was used for the duration of this study. The analytes were separated
in a Kinetex Ci8 column (75 mm x 4.6 mm i.d.) with 2.6-pm superficially porous
particles (Phenomenex, Torrance, CA, USA). The column oven was set to 30°C. The
mobile phase was prepared by on-line mixing of two components (isocratic 1:1 blend).
Component A was prepared by diluting 1.00 mL of 85% H3PO4 (HPLC-grade) to 900 mL
with Type 1 water, adjusting the pH to 2.46 by dropwise addition of NaOH, and diluting
to a final volume of 1 L. Component B was prepared by mixing 200 mL of component A
with 800 mL of HPLC-grade acetonitrile. Both components were filtered using 0.22-pm
nylon membrane filters (Foxx Life Sciences, Salem, NH, USA) and degassed prior to
use. The mobile phase was pumped at a flow rate of 3.0 mL/min. Separation was
completed within 3.5 min. The xenon lamp was operated in “Standard” mode, and the
detector sensitivity settings were adjusted according to the timetable shown in Table 1.

Table 1. Detector settings
Tim e,
min

Excitation A,
nm

E m issio n A,
nm

Sensitivity
level*

0.000

365

445

1

0.760

365

445

5

1.900

365

445

8

*Each sensitivity level represents an 8-fold increase in detector response.
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2.6. METHOD VALIDATION
Validation of the method described here was performed in accordance with the
USP and ICH guidelines. Specific definitions and approaches to the parameters validated
are given below:
2.6.1. Selectivity. Selectivity was determined for each matrix. Spiked and
unspiked samples of each matrix taken from six different animals were individually
processed and analyzed as described above. Chromatograms from spiked and unspiked
samples were compared to determine whether there were any endogenous sources of
interference with the NAC, MPG, and MPA peaks.
2.6.2. Linearity and LLOQ. Linearity was assessed from calibration standards
prepared at nine concentration levels for each matrix. Standards for each calibration point
were prepared in triplicate. Concentration ranges were chosen to reflect those expected
after administration of MPG. For each curve, the concentration of calibration standards
was plotted against the analyte’s peak area relative to that of the internal standard.
Calibration curves were calculated by unweighted linear least-squares regression. The
LLOQ in each matrix was accepted as the lowest standard concentration point on the
curve that exhibited less than 20% RSD from the mean and less than 20% relative
deviation from the target concentration.
2.6.3. Sample Stability. The stability of the processed samples was evaluated for
typical storage conditions, including storage on the autosampler tray at 30°C for up to 12
hours, at 4°C for up to one week, and after three freeze-thaw cycles from -80°C. Stability
of MPG and MPA in sample matrix was also evaluated over 3 hours at room temperature
and 48 hours at -80°C. The determination of sample stability was made using triplicate
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samples matrices spiked with low (166 nM MPG, 83 nM MPA) and high (662 nM MPG,
331 nM MPA) levels of MPG and MPA. Stability was reported as the ratio of the
detector response obtained from samples subjected to the indicated storage conditions to
that of replicate samples injected immediately.
2.6.4. Precision, Accuracy, and Recovery. Precision, accuracy, and relative
recovery were evaluated in each matrix spiked with high (662 nM MPG, 331 nM MPA),
medium (331 nM MPG, 166 nM MPA), and low (166 nM MPG, 83 nM MPA) levels of
MPG and MPA. Five replicate samples were analyzed for each level. Intra-assay
precision is reported as the coefficient of variation (%CV) of five replicate samples
analyzed in the same analytical run. Inter-assay precision is reported as the %CV for 15
replicate spiked samples processed over three different days by two different analysts
with freshly prepared reagents. For determination of relative recovery, spiking solutions
of MPG and MPA were added to samples prior to sample processing. The recovery is
reported as the ratio of the detector response from samples spiked before processing to
the response obtained from analogous samples spiked just prior to derivatization.

3. RESULTS AND DISCUSSION

MPG is an important pharmaceutical for the management of diseases such as
cystinuria and rheumatoid arthritis, and its antioxidant properties may find use in a
number of oxidative stress-related conditions, including cataracts and other age-related
eye diseases. For this purpose, it is necessary to understand the distribution of MPG and
its major metabolite MPA in ocular tissues as well as its absorption into the bloodstream.

46

Moreover, preliminary experiments conducted in our lab suggest that MPA is also a
potent free radical scavenger, and as such, an important contributor to the therapeutic
effects of MPG. In recent years, drug delivery vehicles have emerged as a promising
strategy for increasing drug penetration and residence in the eye. However, in order to
evaluate their ability to increase MPG concentrations in the eye, a sensitive and reliable
method for monitoring MPG levels in ocular tissues needed to be developed and
validated.

3.1. CHROMATOGRAPHY
The method described herein is based on one previously developed by our group
(Penugonda et al., 2004). However, the newer method offers several key advantages over
the original and overcomes some key limitations. Although the method described by
Penugonda et al. was suitable for determination of MPG in a number of other biological
matrices, it was not suitable for our more recent studies investigating ocular drug uptake.
This was mainly due to the presence of endogenous compounds that would co-elute with
MPG. As a result, it was necessary to modify and re-validate the method for this
application. In order to achieve the separation required to eliminate the interference, a
column with higher efficiency was selected, and a new mobile phase composition was
optimized based on the results of typical scouting gradient experiments.
Some representative chromatograms are shown in Figure 3. ThioGlo-3 alone
produced a detectable peak at 3.4 min. Addition of TCEP gave rise to a high intensity
peak that is retained for 0.5 min, and a lower intensity peak with a retention time of 1.7
min. The internal standard, NAC, is retained for 1.1 min. Derivatization of MPG and
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MPA gave rise to two peaks each. Derivatized adducts of MPG were eluted after 1.3 min
and 1.4 min, and adducts of MPA were eluted after 2.3 min and 2.5 min.

Figure 3. Overlay of representative chromatograms from samples containing A, ThioGlo3 in sample diluent; B, ThioGlo-3 + TCEP; C, ThioGlo-3 + TCEP + NAC; D, ThioGlo-3
+ TCEP + NAC + MPA; E, ThioGlo-3 + TCEP + NAC + MPG + MPA. The peaks are
associated with the indicated analytes 1, NAC; 2,3, MPG; 4,5, MPA.

MPG and MPA are both chiral thiols, each containing a single stereocenter. When
these chiral thiols react with a maleimide probe such as ThioGlo-3, a second stereocenter
is formed as shown in Figure 4. Thus, four stereoisomers are possible. (Kullman et al.,
2000) We hypothesize, therefore, that the two diastereomeric pairs were separated due to
the increased chromatographic efficiency of this method. Although multiple products
were formed following derivatization of MPG and MPA, quantitation was not
significantly hindered. The formation of fluorescent adducts following derivatization with
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ThioGlo-3 was quantitative and reproducible, and the results were consistent when using
MPG sourced from different manufacturing lots. Furthermore, baseline resolution was
achieved for all relevant peaks across the working concentration range (resolution > 2.07,
USP). For determination of MPG and MPA, the greatest precision and accuracy were
achieved by integrating the peaks eluting at 1.4 min for MPG and 2.3 min for MPA.

Figure 4. Derivatization of thiols containing a stereocenter gives rise to products with two
stereocenters.

As an isocratic separation that is completed within 3.5 min, this method requires
only 12 mL of mobile phase per run, only 40% of which is organic solvent. Furthermore,
this method offers greater sensitivity than those utilizing UV detection and poses less of
an economic barrier to researchers compared to methods utilizing LC-MS, which can be
prohibitively expensive to acquire and maintain. Thus, the method described here is
faster, more economical, and more environmentally friendly than many existing
techniques.
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3.2. SELECTIVITY
Figure 5 shows representative chromatograms obtained from the analysis of
spiked and unspiked plasma, cornea, lens, and retina extracts. The matrices investigated
did not contain any detectable, endogenous compounds that would co-elute and interfere
with the analytes of interest. Most of the endogenous aminothiols such as GSH, cysteine,
homocysteine, and CysGly elute within the first 60 seconds. The derivatization technique
coupled with the separation and detection method produces interference-free
chromatograms, making the technique selective for NAC, MPG and MPA.

3.3. LINEARITY AND LLOQ
The calibration curves (sample shown Figure 6) were created by plotting the
concentration of calibration standards vs. the analyte’s peak area relative to that of the
internal standard. The regression data from each calibration curve is summarized in Table
2. The linear ranges achieved for MPG and MPA in each of the matrices were suitable for
determinations in real samples. The smallest level on the calibration curve that was
accurate within 20% of the target concentration and with less than 20%RSD was
accepted as the LLOQ for MPG and MPA in each matrix. The LLOQs achieved ranged
from 66 - 99 nM for MPG and were < 33 nM for MPA per 10 pL injection.Given the
drug availability challenges associated with the eye and the relatively small size of the
ocular tissues, low LLOQs are necessary for studies investigating ocular drug uptake and
retention. This is difficult to achieve with other methods available such as those utilizing
UV detection; however, the use of fluorescence detection offers much higher
sensitivity.(Kusmierek, Chwatko, Glowacki, & Bald, 2009) One disadvantage resulting
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from the separation of stereoisomers of MPG and MPA is that the LOD and LLOQ are
increased; however, the limits were still suitable for our applications.

Figure 5. Representative chromatograms from processed tissue samples. Each plot
depicts an overlay of the spiked matrix (B) on top of the unspiked matrix (A). Spiked
matrices contained 500 pmol of NAC, 500 pmol of MPG, and 250 pmol of MPA during
derivatization. Unspiked matrices contained 500 pmol of NAC. Peak labels: 1, NAC ;
2,3, peaks arising from MPG derivatization; 4,5, peaks arising from MPA derivatization.
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Figure 6. Calibration curves for MPG (left) and MPA (right) diluted in SBB. The solid
black dots represent the mean response from three replicate injections.

Table 2. Summary of linear regression
Matrix
SBB
Plasma
Cornea
Lens
Retina

Analyte

Regression equation

R2

MPG

y = 0.1904x - 8.319

0.9991

Linear
range, nM
66 - 1656

MPA

y = 0.4078x - 1.616

0.9997

33 - 828

33.11

MPG

y = 0.0566x - 2.9861

0.9979

66 - 828

66.23

MPA

y = 0.778x - 6.1789

0.9998

33 - 828

33.11

MPG

y = 0.1958x - 12.1028

0.9987

66 - 1656

66.23

MPA

y = 0.442x - 3.085

0.9998

33 - 828

33.11

MPG

y = 0.2363x - 11.5415

0.9997

66 - 1656

66.23

MPA

y = 0.738x - 6.9977

0.9997

33 - 828

33.11

MPG

y = 0.2171x - 15.8672

0.9973

66 - 1656

99.34

MPA

y = 0.4418x - 2.9531

0.9999

33 - 828

33.11

LLOQ, nMa
99.34

aLLOQ is given for an injection volume o f 10 pL.

3.4. SAMPLE STABILITY
Due to the oxidizable nature of the aminothiol analytes and the nature of the
sample, it is important to ensure that the sample will be stable enough under typical
storage and exposure conditions to be reliably analyzed. Since aminothiols are prone to
oxidation, it is recommended to derivatize or otherwise stabilize the samples as soon as
possible. Spiked matrix samples left at room temperature for 3 hours or frozen at -80°C
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for 48 hours before reduction and derivatization provided results within 2% deviation
from samples injected immediately. Processed samples were evaluated at 30°C for up to
12 hours to ensure stability while queued on the autosampler rack. Additionally, stability
was evaluated after storage for 1 week at 4°C, as well as after three freeze-thaw cycles.
The results of these experiments are summarized in Table 3. After the samples have been
processed, they are stable beyond typical handling conditions. All samples were stable at
30°C for at least 12 hours. Acceptable stability was also achieved after storage for up to
one week at 4°C, and after three freeze-thaw cycles of samples stored at -80°C.

Table 3. Stability of derivatized samples

Retina

Lens

Cornea

Plasma

SBB

Spike
Levela

30°C
30°C
4°C
Three freeze-thaw
6 hours
12 hours
1 week
cycles
-------------------------------------------------------------------------------------------------------------MPG
MPA
MPG
MPA
MPG
MPA
MPG
MPA

L

101.9%

97.2%

99.6%

96.9%

96.2%

103.7%

95.9%

98.3%

H

98.6%

98.2%

98.9%

96.2%

99.4%

105.7%

96.1%

93.6%

L

96.3%

103.9%

97.6%

99.2%

97.6%

112.2%

97.6%

105.7%

H

99.9%

98.3%

103.2%

95.3%

100.4%

100.0%

100.5%

96.8%

L

99.5%

97.8%

101.7%

93.8%

100.6%

101.5%

99.2%

98.3%

H

100.0%

100.5%

100.8%

99.8%

99.0%

99.6%

98.9%

96.3%

L

98.0%

98.0%

98.3%

95.7%

97.8%

104.2%

97.7%

103.5%

H

99.3%

97.2%

99.4%

95.0%

99.1%

103.1%

97.7%

99.8%

L

100.0%

100.9%

99.1%

99.8%

97.3%

110.2%

98.1%

111.9%

H

101.0%

100.3%

101.8%

97.9%

97.0%

100.0%

97.7%

100.7%

a Spike levels: L, 166 nM MPG, 83 nM MPA; H, 662 nM MPG, 331 nM MPA
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The convenient one-step reduction and addition of internal standard provides for
greater sample stability with respect to oxidation, evaporation, and processing.
Furthermore, the reduction step allows for determination of total MPG and MPA, by
freeing up protein bound MPG and MPA or other mixed disulfides. This is particularly
important, as their hypothesized mechanisms of action involve thiol-disulfide exchange,
indicating that a significant portion of MPG and MPA may be oxidized at their sites of
action.

3.5. PRECISION, ACCURACY, AND RECOVERY
Precision, accuracy, and relative recovery were determined according to the USP
and ICH guidelines. The results are summarized in Table 4.

Table 4. Precision, accuracy, and recovery
Matrix
SBB

Plasma

Cornea

Lens

Retina

Spike
Levela
L
M
H
L
M
H
L
M
H
L
M
H
L
M
H

Precision
Intra-day
Inter-day
(%CV)
(%CV)
MPG MPA MPG MPA
0.51
1.11
3.00 2.16
0.34
1.38 2.28 2.23
0.16 0.52 0.56
1.07
4.15 3.03 6.99 3.65
5.40 0.76 5.89 2.83
2.59
1.29 2.72 2.32
0.65 0.98 3.40
1.32
0.29 0.55 2.09
1.68
0.10 0.30 0.78 0.67
2.04 2.17 4.50 2.67
0.60
1.01
3.61
1.48
0.60 0.69
1.23 0.75
0.84
1.95
1.01
2.28
0.21
0.67
1.96 2.25
0.26 0.30
1.16
1.04

Accuracy

Relative Recovery

(%RE)

(%, mean ± S.D.)

MPG
10.14
1.99
0.74
-10.25
-8.74
-13.25
-3.06
5.42
5.66
-4.63
-7.31
-5.02
4.11
0.43
1.26

MPA
-3.85
-3.72
-1.13
5.16
1.50
-1.19
-2.49
-4.14
-4.26
5.45
0.98
1.77
-3.34
-2.76
-4.79

MPG
n.a.
n.a.
n.a.
111.3 ± 2.39
104.5 ± 4.43
111.4 ± 8.07
98.3 ± 0.14
96.4 ± 0.59
99.9 ± 1.60
110.9 ± 2.96
111.7 ± 0.53
111.3 ± 0.72
99.4 ± 0.45
99.5 ± 1.43
101.4 ± 1.92

MPA
n.a.
n.a.
n.a.
97.4 ± 2.36
98.8 ± 1.56
102.4 ± 1.13
100.1 ± 1.71
102.3 ± 0.61
102.0 ± 0.38
99.1 ± 4.08
102.5 ± 1.50
102.5 ± 1.97
104.5 ± 0.34
103.3 ± 0.50
105.0 ± 0.36

a Spike levels: L, 166 nM MPG, 83 nM MPA; M, 331 nM MPG, 166 nM MPA; H, 662 nM
MPG, 331 nM MPA
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Intra-day and inter-day precision for all samples were below 5.5% and 7.0% RSD,
respectively. Determinations in plasma samples were accurate within 13.3% of the spiked
concentration while those from ocular tissues were accurate within 7.4% of the spiked
concentration. The relative recovery was consistent across low, medium, and high spikes
of MPG and MPA within matrices. All values were within the acceptability criteria.

3.6. DETERMINATION OF MPG AND MPA IN PLASMA AND OCULAR
TISSUES
The method validated as described above was successfully applied for the
simultaneous determination of MPG and MPA in Wistar rat plasma and ocular tissues
following injection of MPG. Wistar rats were administered PBS or MPG (250 mg/kg
body weight) by intraperitoneal injection. This dose is relatively high compared to those
used in human patients, which was necessary in order to observe even low levels of MPG
in ocular tissues. None of the animals were given MPA. Samples were processed as
described in the methods section. The results are summarized in Table 5.

Table 5. MPG and MPA concentration in Wistar rat tissues 40 min after intraperitoneal
administration of MPG
Sample

[MPG]
[MPA]
Mean ± Standard Deviation (N = 3)

Plasma

88.30 ± 9.13 pM

9.13 ± 3.50 pM

Cornea

11.93 ± 1.36 nmol/mg protein

1.36 ± 1.06 nmol/mg protein

Lens

0.41 ± 0.12 nmol/mg protein

0.12 ± 0.07 nmol/mg protein

Retina

2.43 ± 1.42 nmol/mg protein

Not detected
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No MPG or MPA was detected in samples collected from animals injected with
PBS. Both MPG and MPA were present in plasma, cornea, and lens samples from the
animals that were injected with MPG. Since MPA was not detected in the animals
injected with PBS, this indicates that MPG was metabolized to MPA following injection.
The retina did not contain detectable levels of MPA, but low levels of MPG were present.
Although a similar method for analysis of MPG in biological tissues was
developed in our lab and described by Penugonda (Penugonda et al., 2004), endogenous
interferences prevented determination of MPG in lens tissue, and thus it was unsuitable
for evaluating ocular uptake of MPG. Furthermore, the method described here offers a
number of significant improvements over the previous method: First of all, this method
simultaneously measures concentrations of MPA as well as MPG. In addition, TCEP
reduction allows for determination of total MPG, comprising its oxidized and reduced
forms. The current method’s use of an internal standard greatly improves accuracy and
robustness. Finally, the new method is twice as fast. Therefore, this method is more
suitable for evaluating drug delivery vehicles designed to enhance the ocular uptake of
MPG.

4. CONCLUSION

A reliable HPLC-FLD method was developed for simultaneous determination of
MPG and its major metabolite, MPA. Because this drug exhibits potential as an
antioxidant treatment for cataracts, the method was validated in ocular tissue matrices
and plasma for the purpose of monitoring the uptake and distribution of the drug
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throughout treatment. The method was successfully applied to the analysis of plasma and
ocular tissues of animals injected with MPG, wherein both analytes MPG and MPA were
detected in animals treated with the drug. While other techniques for the analysis of MPG
exist, the method described here accomplishes it isocratically in under 4 minutes with
widely available instrumentation. Moreover, the reduction step and internal standard
confer stability with respect to oxidation during processing and other variations in sample
handling, making this method ideal for routine analysis of MPG and MPA in both basic
research and clinical settings.
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ABSTRACT

Tiopronin is an FDA-approved thiol drug currently used to treat cystinuria and
rheumatoid arthritis. However, due to its antioxidant properties, it may be beneficial in a
variety of other conditions. One primary obstacle to its wider application is its limited
bioavailability, which necessitates administration of high systemic doses to achieve
localized therapeutic effects. Incorporation of a drug delivery vehicle can solve this
dilemma by providing a means of controlled, targeted release. Functionalized
nanodiamond is a promising theranostic platform that has demonstrated great potential
for biomedical applications, including drug delivery. Design of nanodiamond theranostic
platforms requires comprehensive understanding of drug-platform interactions, and the
necessary physical chemical investigations have only been realized for a limited number
of compounds. Towards the long-term goal of developing a nanodiamond-tiopronin
treatment paradigm, this study aims to shed light on the effects of nanodiamond surface
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chemistry on adsorption and release of tiopronin. Specifically, adsorption isotherms were
measured and fit to Langmuir and Freundlich models for carboxylated, hydroxylated, and
aminated nanodiamonds, and release was monitored in solutions at pH 4.0, 5.8, 7.3, and
8.1. Our results indicate that aminated nanodiamonds exhibit the highest loading capacity
while hydroxylated nanodiamonds are the most effective for sustained release. Therefore,
a high degree of flexibility may be afforded by the use of nanodiamonds with different
surface chemistries optimized for specific applications.
Keywords: Nanodiamond; Functionalization; Adsorption; Desorption; Drug delivery

1. INTRODUCTION

Tiopronin is a low-molecular-weight thiol drug used for the treatment of
rheumatoid arthritis and cystinuria. It has also demonstrated potential benefits in a variety
of other conditions, including heavy metal1 and radiation poisoning,2 and cataract.3 A
primary mechanism of its action in these conditions is the direct scavenging of free
radicals and maintenance of healthy levels of glutathione (GSH), a vital antioxidant and
the body's most abundant non-protein thiol.4-5However, the effectiveness of tiopronin is
limited by its bioavailability. Tiopronin is weakly acidic and becomes deprotonated at
physiological pH. The negatively charged conjugate base (Figure 1) cannot easily
penetrate the low polarity lipid bilayer of cell membranes. Furthermore, when
administered topically, insufficient residence time on physiological barriers such as the
skin or cornea can severely curtail its uptake and deeper penetration into tissues.6 These
effects necessitate the administration of higher dosages, increasing the risk and severity
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of adverse side effects. It is therefore desirable to provide a means by which small
hydrophilic molecules such as tiopronin can be transported and released in a controlled
manner at their desired site of action. Towards this end, drug delivery vehicles offer a
promising alternative to the large systemic doses of neat drug and excipient used
currently.7 For example, it has been shown that poloxamer hydrogels significantly
enhanced uptake and effectiveness of tiopronin in a rat model of age-related nuclear
o

cataracts.8

In addition to providing controlled transport and release of a well-defined and
therapeutically consequential payload, drug delivery vehicles must be highly
biocompatible and stable under formulation conditions (which may include autoclaving
or irradiation). Sustained release is also desirable, given that the conditions mentioned
above may be long-term or chronic illnesses. In these respects, hydrogels present many
challenges with regard to chemical stability, longevity, and especially sustained and
controlled release.9 Nanodiamonds (NDs), however, are not subject to these limitations.
Detonation nanodiamonds, which are inexpensive and commercially available, are
nontoxic and are considered the most biocompatible of all carbon nanoparticles.10 Each
ND particle possesses a core of sp3 hybridized carbon that is chemically inert and similar
to bulk diamond, while the surface comprises fully exposed, covalently attached
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functional groups that can be tailored for optimal interaction with the drug payload and
environment.10-11 Modification of surface chemistry affords a high degree of control,
specificity, and flexibility with respect to drug-ND interaction.12-14 Here we investigate
the potential of ND as a promising candidate platform for delivery and sustained release
of tiopronin.
A critical step in assessing the suitability of a drug delivery platform is to
determine its capacity to carry and release the compound of interest.
Adsorption/desorption is the simplest and therefore preferred mechanism of loading and
release. It requires no chemical modification of the drug, which reduces risks of
interfering with its biological activity.13 The rich surface chemistry of ND allows for a
high degree of control over drug-ND interactions, which is exerted through the creation
of functional groups such as -COOH, -OH, or -NH2 on the ND surface. Controlling ND
surface chemistry can significantly affect loading capacity, strength of binding, and
release of the desired drug.14 Because tiopronin is negatively charged at physiological
pH, the electrostatic interaction between adsorbent and adsorbate can be tailored to
optimize the drug delivery platform.
Although understanding adsorption and release is essential for development of
ND-drug complexes capable of delivering well-defined dosages, these phenomena have
been largely unexplored for ND as a carrier of tiopronin or other similar thiol drugs. By
understanding the effects of surface functionalization on ^-potential, adsorption
monolayer capacity, and cumulative drug release, we can determine the optimal surface
chemistry for ND-mediated delivery of tiopronin for a variety of conditions. Consistent
and reliable delivery of tiopronin and related compounds can pave the way for more
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targeted treatment regimens that produce the same therapeutic effects with significantly
lower incidence of side effects.

2. EXPERIMENTAL METHODS

2.1. MATERIALS AND REAGENTS
UD90 ND powder was donated by NanoBlox, Inc. Tiopronin, tris(2carboxyethyl)phosphine (TCEP), N-acetylcysteine (NAC), and K2HPO4 were purchased
from MilliporeSigma (St. Louis, MO, USA). ThioGlo-3 was purchased from Covalent
Associates Inc. (Bellingham, WA, USA). All other reagents were purchased from Fisher
Scientific (Pittsburgh, PA, USA). Type 1 water was prepared in-house using a Millipore
Simplicity 185 purification system (MilliporeSigma). Citrate-phosphate buffers were
prepared to the desired pH by mixing 0.1 M citric acid with 0.2 M Na2HPO4 in varied
ratios as shown in Table S1. The pH 8.1 buffer was prepared by dissolving 1.628 g of
K2HPO4 and 0.089 g of KH2PO4 in type 1 water and then diluting to a final volume of
100 mL in a volumetric flask.

2.2. PURIFICATION AND SURFACE MODIFICATION OF ND
To remove non-diamond carbon, 2.0 g of as-received ND were placed into a 50
mL porcelain crucible and heated in air at 425°C for 2 hours in a Thermolyne 2L D1
Benchtop Muffle Furnace (Thermo Scientific).15 Then, the NDs were refluxed overnight
in 50 mL (1:1) volume of 35 wt. % aqueous HCl : 70 wt. % aqueous HNO3 to remove
traces of metals and metal oxides and to hydrolyze surface anhydrides. The mixture was
then allowed to cool to ambient temperature. Excess acids were removed by decanting
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followed by several cycles of rinsing and centrifuging with deionized water until the pH
was neutral. Then, the mixture was dried in a desiccator with drierite under vacuum at
ambient temperature for about two days, yielding a purified carboxylated ND (NDCOOH). This ND-COOH was used as a starting material for the synthesis of all other
functionalized NDs in this work.
Aminated ND (ND-NH2) was produced in two stages: 1) conversion of NDCOOH to acyl chloride ND (ND-COCl), 2) reaction of ND-COCl with ethylenediamine
(EDA).16 In the first stage, a mixture of 1.0 g of ND-COOH in a 100 mL round-bottom
flask with a Teflon-coated magnetic stirrer bar, 50 mL thionyl chloride (SOCh), and 0.5
mL of anhydrous dimethylformamide (DMF) as a catalyst was sonicated in an ultrasonic
bath to break all visible ND agglomerates. The flask was then connected to a condenser
closed with a drierite-filled drying tube and heated overnight under reflux at ~70 °C to
yield ND-COCl. The flask was then cooled to ambient temperature, and excess SOCl2
was removed by vacuum distillation at < 50 °C to suppress thermal decomposition of
SOCl2 . The residual solid was rinsed six times with 50 mL anhydrous THF, and excess
THF was decanted. The solid was then dried overnight in a desiccator containing drierite
under vacuum at ambient temperature. In the second stage, 1.0 g of dry ND-COCl was
mixed with 50 mL anhydrous ethylenediamine in a 100 mL round-bottom flask
containing a Teflon coated magnetic stirrer bar. The mixture was sonicated in an
ultrasonic bath until all visible agglomerates of nanodiamond disappeared. The flask was
then connected to a condenser closed with a drierite drying tube and heated overnight at
~60 °C under reflux. After cooling to ambient temperature, ND-NH2 powder was
precipitated, and excess EDA was gently removed using a pipette. The resulting ND-NH2
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powder was rinsed six times with 50 mL fresh anhydrous THF to remove any traces of
adsorbed EDA. A few drops of THF from the last wash were mixed with ~10 mL of
deionized water, and the pH of the solution was measured to test for complete removal of
EDA, as indicated by neutral pH. The resulting ND-NH2 was dried on a watch glass at
room temperature in ambient air. Aminated ND was characterized as reported before.16
Hydroxylated ND (ND-OH) was synthesized as described previously.17 1.0 g NDCOOH was purged several times with argon gas in a 250-mL Schlenk flask containing a
Teflon-coated magnetic stirrer bar. Anhydrous tetrahydrofuran (THF) was degassed by
purging with argon gas for one hour. 5 mL of degassed THF was added to the Schlenk
flask containing ND-COOH, and the mixture was sonicated to break all visible
agglomerates. Then, 10 mL of a 2.0 M solution of lithium aluminum hydride (LiAlH4) in
THF was added. The mixture was stirred overnight at ambient temperature under argon.
The excess of (LiAlH4) was quenched by dropwise addition of 1 M HCl. Then, 1 M KOH
was added until neutral pH. The product was rinsed and centrifuged several times with
water and finally with acetone. The resulting ND-OH was dried overnight at 90 °C.

2.3. CHARACTERIZATION OF FUNCTIONALIZED ND
Transmission Electron Microscopy (TEM) was carried out using an FEI Tecnai
G2 F20 S-TWIN transmission electron microscope equipped with field-emission gun,
operated at 200 kV. TEM samples were prepared by drop-casting aqueous ND
suspensions onto carbon-coated copper grids followed by drying in the ambient
atmosphere. Additional structural information was obtained by small-area electron
diffraction (SAED), performed using the same instrument. X-ray diffraction (XRD)
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analysis of as-received ND was conducted using a PANalytical X’Pert multipurpose
diffractometer (Malvern Instruments, Ltd., Malvern, UK), powered by a Philips
PW3064/60 X-ray generator with a Cu Ka (X = 1.540598 A) radiation source. Fourier
Transform Infrared (FTIR) spectra were recorded using a Thermo Nicolet NEXUS 470
FT-IR Spectrometer, in a range 400-4000 cm-1 with 1 cm-1 resolution. Pellets were
prepared by pressing a mixture of 2 mg ND and 200 mg KBr under a load of 10-15 tons.
A Zetasizer Nano ZSP and an MPT-2 multi-purpose titrator (Malvern Instruments, Ltd.)
were used to determine Z-potential and size of the ND agglomerates as a function of pH
(Z-potential titration) at 23 °C. For all NDs, 10 mL of 0.01 wt. % ND colloidal solution
was used to measure Z-potential and average particle size with 0.5 pH steps over a pH
range 2.0 - 9.0 with three measurements at each pH. To minimize initial aggregation, for
negatively charged ND-COOH the starting pH was 9.0, and for positively charged NDNH2 and ND-OH the starting pH was 2.0. The titrator was thoroughly cleaned and primed
after every sample measurement to avoid contamination and remove air bubbles, and the
pH probe was properly calibrated to ensure accurate results.

2.4. ADSORPTION STUDY
ND stock suspensions were prepared in pre-weighed, reinforced RINO
microcentrifuge tubes (Next Advance, NY, USA) by dispersing functionalized NDs in
type 1 water at a nominal concentration of 1.4 wt. %. The actual concentration of each
stock solution was determined by weighing the NDs and the ND-water suspension. The
NDs were dispersed by bombarding the outsides of the RINO tubes in a Bullet Blender
Storm (Next Advance) at max speed for 10 min. The tubes were then sonicated in an
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ultrasonic bath for 20 min. The tubes containing ND stocks left to equilibrate to room
temperature on a rotator. The contents of the tubes were vigorously vortexed immediately
before any liquid transfer procedures. The density of each stock ND suspension was
determined by weighing aliquots measured out with a volumetric pipette. The density
was used to convert the concentration from mg ND/g solution to units of mg/mL.
Appropriate dilutions were made to aliquots of ND stocks with type 1 water to yield a
working concentration of 2.00 mg/mL. An 804 ppm stock solution of tiopronin was
prepared by dissolving 80.4 mg of tiopronin in type 1 water in a 100-mL volumetric
flask. All working solutions were prepared by dilutions of this stock solution. In 2-mL
microcentrifuge tubes, 500 pL of 2.00 mg/mL ND working solutions were mixed with
500 pL of the appropriate working tiopronin solution to produce samples containing 1
mg/mL functionalized ND and 0-200 ppm tiopronin. The samples were thoroughly mixed
by vortexing and placed on a rotator for 24 hours. After this time, the samples were
placed in a centrifuge and subjected to 12,000 x g for 12 min. The supernatants were
collected and centrifuged again at 12,000 x g for 12 min to remove any remaining NDs.
Free tiopronin was determined in the supernatant using a sensitive HPLC technique
described previously.18 Briefly, the supernatant was diluted as necessary, and 25 pL of
supernatant was added to 100 pL of reducing buffer (75 pM TCEP and 2.5 pM NAC in
pH 7.0 citrate-phosphate buffer). The sample was then derivatized by the addition of 375
pL of 33 pM ThioGlo-3. The derivatized sample was acidified by the addition of 5 pL of
2 M HCl and diluted with 250 pL of 15 mM H3PO4 . Finally, the sample was filtered and
subjected to HPLC analysis. The calibration standards were processed in parallel with the
unknown samples.
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2.5. RELEASE STUDY
The release study methodology was adopted from a previous investigation.13
NDs were loaded with tiopronin by mixing 6.1 mL of 2.00 mg/mL ND in 15-mL
centrifuge tubes with 6.1 mL of 80, 200, or 400 ppm tiopronin for ND-COOH, ND-OH,
and ND-NH2, respectively. These concentrations were selected based on the maximum
monolayer adsorption capacity of each ND type, as determined in the adsorption study.
The tubes were placed on a rotator for 24 hours to equilibrate. After this time, 12 mL of
each loaded ND sample was divided into 12 pre-weighed 2-mL microcentrifuge tubes.
The loaded NDs were centrifuged as described previously, and the supernatants were
carefully removed with a pipette. The supernatants were analyzed in the same manner as
the adsorption samples to determine the amount of tiopronin adsorbed in each sample. To
wash away unbound tiopronin, the loaded NDs were rinsed with 1000 pL of type 1 water.
The samples were centrifuged to precipitate the NDs, and the water was carefully
removed with a pipette. This step was repeated once more. After washing, the loaded ND
precipitates were dried under vacuum in a Vacufuge Concentrator 5301 (Eppendorf,
Hauppauge, NY, USA) heated to 60°C. The NDs were left to dry for at least 3 hours,
until they had a dry, cracked appearance. The mass of ND remaining in each tube was
determined by subtracting the weight of the empty tube from that of the tube with dried
NDs. The weight of adsorbed tiopronin molecules was negligible. To investigate the
relationship between pH and tiopronin release, the loaded NDs were divided into four
groups per ND type (pH 4.0, 5.8, 7.3, and 8.1) with 3 replicates per group. The loaded
NDs were resuspended by vortexing in a buffer solution with a pH corresponding to the
group. The volume of buffer added was based on the mass of ND remaining in each tube
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after rinsing and drying such that the ND concentration would be 1 mg/mL. The tubes
were placed on a rotator during the desorption study. Every 24 hours, the tubes were
centrifuged to precipitate the NDs as described previously. Sample volumes equal to 15%
of the total buffer volume were collected from the supernatant solution for tiopronin
analysis. This volume was replaced with an equal volume of fresh buffer, and the NDs
were resuspended by vortexing. The tubes were then returned to the rotator. The samples
were analyzed for tiopronin in the manner described in previous sections, however,
separate calibration standards were prepared for each of the pH 4.0, 5.8, 7.3, and 8.1
buffers to account for matrix effects during analysis (Figures S1-4). Determinations of
statistical significance were made using two-way ANOVA followed by a Bonferroni post
hoc test using GraphPad Prism 5.

3. RESULTS AND DISCUSSION

3.1. CHARACTERIZATION OF FUNCTIONALIZED ND
Representative TEM micrographs of ND-COOH are shown in Figure 2. Figure
2A shows a low-resolution image of an ND-COOH sample, which reveals typical
morphology of detonation nanodiamonds dried on TEM grid. The sample appears
uniform, and although separate single nanodiamond particles were found in the sample,
larger clusters were primarily observed. The high resolution TEM image of ND-COOH
in Figure 2B shows 0.206 nm (111) d-spacing of crystalline diamond. The selected-area
electron diffraction (SAED), shown in Figure 2C, confirms the diamond crystalline
structure of the ND-COOH particles, with strong SAED rings corresponding to (111),
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(220), and (311) planes of ND with d-spacing of 0.206 nm, 0.127 nm, and 0.109 nm,
respectively. The measured d-spacing values match well with the structure of cubic
diamond. 19-20 XRD of the as-received ND (Figure 3A) shows three prominent peaks
consistent with diffraction of diamond at 29 = 43.9°, 75.2° and 91.3° indexed as (111),
(220) and (311) planes in cubic diamond.

Figure 2. A. Low resolution and B. High resolution TEM micrographs of ND-COOH
showing 0.206 nm d-spacing. C. Selected area electron diffraction pattern of ND-COOH
sample consistent with small ND primary particle size and diffraction rings
corresponding to the (111), (220), and (311) planes of diamond.

Surface chemistry of ND, ND-COOH, ND-OH and ND-NH2 was characterized
by FTIR spectroscopy (Figure 3B-C). Figure 3C confirms covalent bonding of amino
groups to ND surface in ND-NH2 . The peaks at 3418 cm-1 present in all ND spectra
correspond to O-H stretching vibrations and could be assigned to O-H or adsorbed
water.21 The C-H stretch bands at ~2870 and ~2923 cm-1 originate from hydrogen atoms
attached to ND surface, as well as from CH2 groups of EDA in ND-NH2 . The bands at
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1637 cm-1 and ~3418 cm-1 in ND-NH2 arise from the bending and stretching modes of NH as well as remaining O-H bonds.21-22 ND-NH2 amide peaks correspond to blue-shifted
Amide I (1667 cm-1) and Amide II (1520 cm-1), as well as Amide III (~1320 cm-1)
(Figure 3C).22 A small C=O band at 1776 cm-1 in ND-NH2, suggests the presence of
carbonyl species (carboxylic acids, ketones, esters, etc.) in the ND-NH2.16
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Figure 3. A. XRD pattern of as-received ND. B. FTIR spectra of as-received ND, NDCOOH, ND-OH, and ND-NH2 . C. FTIR spectra of ND-COOH and ND-NH2 in the range
of wavelength corresponding to Amide bands. Dashed lines indicate absorbance
corresponding to major functional groups D. Z -potential vs. pH and E. Mean diameter of
ND agglomerates vs. pH for ND-COOH (•), ND-OH (■), and ND-NH2 (▲). Reported as
mean ± standard deviation. Arrows indicate direction of titration for each type of ND.
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The effect of pH on Z-potential was investigated for ND-COOH, ND-OH, and
ND-NH2 (Figure 3D) to make predictions about electrostatic interactions between
tiopronin and NDs. ND-COOH has a strongly negative Z-potential above pH 3.8 due to
deprotonation of ND-COOH to ND-COO-. ND-OH has a moderately positive Z-potential
in acidic and neutral pH with an isoelectric pH 7.9, above which a negative Z-potential
was observed. The positive Z-potential in acidic pH may result from ND-OH protonation
or the presence of hydrogen terminations (ND-H) formed during the preparation of NDOH. ND-H has been previously reported to exhibit a highly positive Z-potential for
reasons that are not entirely clear.22-23 ND-NH2 has a weakly positive Z-potential in acidic
pH with an isoelectric pH 6.1, above which it has a weakly negative Z-potential. Although
ND-NH2 is expected to have a more strongly positive Z-potential in acidic pH compared
to ND-OH, contribution from remaining COOH groups in ND-NH2 (also seen in FTIR)
results in a surface with mixed electrostatic affinity and a lower net Z-potential. The effect
of pH on the size of ND agglomerates was also investigated. The results are shown in
Figure 3E. For ND-COOH, pH had a significant impact on the extent of agglomeration.
The nominal size of ND-COOH clusters was 200 nm for pH > 4. Below pH 4, significant
aggregation of ND-COOH was observed, with particle sizes ranging from 3.4 to 5.7 p,m.
This observation can be attributed to protonation of the carboxylate group, resulting in
reduction of the magnitude of Z-potential as indicated in Figure 3D and, consequently, a
significant decrease in colloidal stability. For ND-OH, average size increased with
increasing pH, with sizes ranging from 0.8 to 5.7 p,m. This is also in agreement with the
Z-potential titration data, which shows that the magnitude of ND-OH Z-potential drops
with increasing pH, leading to weaker electrostatic repulsion between individual particles
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w hich confers colloidal stability. F o r N D -N H 2 , the effect o f pH on size w as m uch less
pronounced. T he average diam eter o f N D -N H 2 agglom erates ranged from 2.5 to 3.2 pm.
T his result is reasonable considering N D -N H 2 has a m ix o f carboxylate and am ine
surface m oieties and exhibited only sm all changes in net Z-potential over the tested pH
range.

3.2. ADSORPTION OF TIOPRONIN
A dsorption isotherm s w ere constructed by plotting the equilibrium tiopronin
concentration (Ceq) follow ing adsorption vs.

A, the am ount o f adsorbed drug per gram o f

N D , calculated by taking the difference o f the tio p ro n in initial solution concentration ( Co)
and the equilibrium concentration after 24 hours. The experim ental adsorption isotherm s
(Figure 4) w ere fit by no n lin ear least-squares regression to L an g m u ir and F reundlich
m odels. The L angm uir m odel (E quation 1) assum es th at all adsorption sites are identical
w ith respect to affinity for adsorbate and energy o f adsorption.

A = Am a x

Ceq
l+ K iC eq

(1)

T his m odel also assum es th at all adsorbed m olecules are in contact w ith the
adsorbent (i.e., m o n o lay er adsorption).25 In E q uation 1, Amax represents the m axim um
m onolayer adsorption capacity o f the adsorbent, and K l represents the strength o f
binding. T he F reundlich m odel (E quation 2), in contrast, accom m odates m ultilayer
adsorption and adsorbent surface h eterogeneity.26 In this em pirical m odel, K f and n are
relative indicators o f adsorption capacity and favorability, respectively.
A = K FCgqn

(2)
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F igure 4. A -C . L an g m u ir (solid red line) and F reundlich (blue dashed line) fits to
experim ental adsorption isotherm s o f A. N D -C O O H , B. N D -O H , and C. N D -N H 2 . D.
O verlay o f L an g m u ir fits from A-C.

F o r all three N D s,
than 0.97.

R values for adsorption data fits to either m odel are all greater

A max values fo r N D s change in the follow ing order: N D -C O O H < N D -O H <

N D -N H 2 (T able 1). The sam e trend is observed fo r K f values. N eith er the L angm uir
b inding strength

Kl no r the F reundlich adsorption favorability param eter n follow s this

trend: both are highest fo r N D -C O O H , b u t N D -O H has the low est Kl , w hile N D -N H 2 has
the low est

n . O verall, the L angm uir m odel fits the experim ental data m ore closely than

the F reundlich m odel for all three N D s investigated here. This indicates th at the
interaction o f tiopronin w ith the N D surface m ay be understood largely in term s o f the
L an g m u ir m odel and m onolayer adsorption. Specifically, the param eters

A max and Kl

derived from this m odel can be u sed to com pare the properties o f functionalized N D s as
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adsorbents for tiopronin and to predict their relative effectiveness for different
applications. Parameters for each of the fits, as well as the resulting Pearson’s correlation
coefficients (R) are shown in Table 1.

Table 1. Parameters and Pearson’s correlation coefficient for Langmuir and Freundlich
curve fits to adsorption data
Langmuir

ND

Freundlich

Amax (mg/g)

Kl (mL/mg)

R

n

Kf

R

COOH

7.54

295

0.986

3.87

17.3

0.976

OH

42.9

49.8

0.989

2.21

118

0.971

NH2

210

76.2

0.996

2.01

824

0.980

Tiopronin is a weak acid, with a -COOH pKa of 3.9. Therefore, a significant
proportion of the dissolved tiopronin will become negatively charged in water. NDCOOH exhibits negative Z-potential. Thus, the low monolayer adsorption capacity of the
ND-COOH may be explained by electrostatic repulsion between the deprotonated NDCOO- and the deprotonated tiopronin. The high adsorption capacity of the ND-NH2 may
be the result of other factors. Under the mildly acidic conditions of the adsorption studies,
ND-OH possesses a more strongly positive Z-potential than ND-NH2 (Figure 3D), yet it
has a lower Amax. This suggests that the higher adsorption capacity of ND-NH2 cannot be
explained solely in terms of electrostatic attraction between positively charged surface
functional groups and tiopronin. It therefore becomes necessary to consider the effects of
colloidal stability on available adsorption sites. Agglomerates formed more readily by
less positively charged ND-NH2 exhibit greater variation in available adsorption sites,
including areas where tiopronin may accumulate and be trapped, leading to greater
apparent Amax and binding strength of ND-NH2 27 While exhibiting a stronger electrostatic

76
attraction to the anionic tiopronin, the greater net positive charge, in addition to the
capacity fo r extensive h ydrogen bonding w ith w ater, is tho u g h t to stabilize the N D -O H
particles in the suspension, resulting in less agglom eration and few er such sites o f
hindered desorption.
F igure 5 show s a plot o f Amax vs.

Kl fo r N D s w ith different surface chem istries

studied here. A lthough the und erlying m echanism s have not been w ell-established for the
v a st m ajority o f drug-N D system s, th e apparent discrepancy betw een drug binding
strength and adsorption capacity has b een reported b e fo re 13-14, 26 and indicates th at these
characteristics m ay be independently tailored to m eet the needs o f different applications.
T he ability to design N D drug delivery system s w herein both loading capacity and
b inding strength can be m odified to suit the application is extrem ely attractive, as safe
and effective delivery o f drugs w ith different potencies and toxicities w arran t highly
tailorable vehicles th at can carry and release the drug as required. Furtherm ore, the gap
betw een acknow ledgm ent o f th eir evident utility and com m and o f the m echanism s
responsible, m ay provide greater im petus fo r further investigations o f N D theranostic
platform s.

F igure 5. A.

Kl vs. A max B. Separation factor Rl vs. Co
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Separation factor Rl is related to

Kl by equation 3, w here Co is the initial

concentration o f adsorbate. T he value o f Rl indicates w h ether adsorption is irreversible
(Rl = 0), favorable (0 <

Rl < 1), or u nfavorable (Rl > 1) at the initial concentration o f

adsorbate.28

R, =

i
1 + K LCo

G iven th at Kl values ranged from 76.2 and 295 m L /m g,

(3)
Rl values approach 1 as

Co approaches 0 m g/m L and 0 as Co approaches infinity. T herefore, adsorption o f
tiopronin onto functionalized N D is favorable at any concentration and becom es m ore
favorable as concentration increases.29

3.3. RELEASE STUDY
T iopronin is negatively charged at physiological pH (7.4), and therefore cannot
readily cross the phospholipid bilay er o f m o st cell m em branes by passive diffusion. N D m ediated delivery o f tio pronin across the m em branes in a form o f a thin (m onom olecular)
adsorbed layer m ay circum vent this problem , w hile potentially im proving bioavailability
o f the drug. In addition, since b oth tio pronin and functionalized N D s have pH -labile
protons, w e exam ined the potential fo r pH -triggered relase o f tio p ro n in from N D s.
T iopronin-loaded N D -C O O H , N D -O H , and N D -N H 2 w ere dispersed at 1 m g/m L in
buffers ranging from pH 4.0 to 8.1. T he am ount o f tiopronin released w as m easured daily
fo r the first ten days after w hich m easurem ents w ere taken every 2-3 days. N o significant
release w as observed bey o n d 12 days. To u n derstand the effect o f pH on tio p ro n in release
fo r each functionalized N D , the cum ulative release as a percentage o f adsorbed tiopronin
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was plotted vs. time (Figure 6A-C). Additionally, cumulative release after 1 day and 12
days was compared across the different ND surface chemistries (Figure 6D-E).

Figure 6. A-C. Plots of cumulative tiopronin release as a percentage of the initial amount
of adsorbed tiopronin vs. time for A. ND-COOH, B. ND-OH, and C. ND-NH2 in pH 4.0
(•), 5.8 (■), 7.3 (▲), and 8.1 (▼) buffer. Error bars are standard error of the mean
(o/Vri ). D-E. Cumulative tiopronin release after 1 day and 12 days, expressed as D.
percentage of the initial amount of adsorbed tiopronin and E. mass of tiopronin released
per gram of ND. The error bars are standard error of the mean. The pH of the desorption
buffer is indicated above each corresponding bar.
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Table 2. Calculated distribution of tiopronin microspecies and Z-potential of ND
suspensions
Estimated Microspecies Distribution (%) *

o

pH

Z -potential (mV)
ND-COOH

ND-OH

ND-NH2

4.0

42.27%

57.73%

0.00%

-22.6

+14.5

+5.95

5.8

1.15%

98.82%

0.03%

-34.1

+11.3

+0.86

7.3

0.04%

99.08%

0.88%

-36.2

+4.46

-4.99

8.1

0.01%

94.64%

5.35%

-37.8

-1.57

-7.23

*Chemicalize from ChemAxon was used for calculation of estimated microspecies
distribution, Feb, 2019, https://chemicalize.com

Table 2 shows calculated microspecies distribution of tiopronin and Z-potentials
determined for each functionalized ND at relevant pH levels. The majority of tiopronin is
negatively charged over the tested pH range, with > 57% deprotonated at pH 4.0 and >
99% deprotonated at pH 5.8 - 8.1. Thus, it was expected that release will generally
increase under higher pH conditions which reduce the number of positive charges on the
ND surface.
Figure 6A shows that pH had a minimal effect on the total amount of tiopronin
released from ND-COOH. The difference in means with respect to release was
statistically significant only between pH 4.0 and 8.1, but only after 5 days. This result is
unsurprising since ND-COOH retains a highly negative Z-potential, even at pH 4.0. For
this reason, ND-COOH may be useful for applications which require pH-independent
release of tiopronin. It is also worth mentioning that because of the large number of
negative surface charges on ND-COOH, it is much easier to maintain a small particle size
distribution; even single-digit NDs can be prepared from ND-COOH without milling
using salt-assisted ultrasonic deaggregation (SAUD).30 The pH also had a minimal effect
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on the release of the tiopronin from ND-NH2 (Figure 6C). The difference in means can
only be considered statistically significant between pH 6 and 7, and only after 8 days.
The Z-potential plot in Figure 3D suggests that a number of COOH moieties remain on
the surface of ND-NH2 . These groups are negatively charged within the pH range used in
this study, contributing to the net surface charge and resulting in a low magnitude Zpotential. Although the means suggest that more release occurs at pH 4.0 than at pH 5.8,
the difference between the means is statistically insignificant. The same is true for the
means of pH 7.3 and 8.1. From a practical standpoint, no appreciable difference in release
will be achieved by varying pH in the range of 4-8 for ND-NH2 or ND-COOH. The pH
had the greatest effect on tiopronin release from ND-OH. The effect of pH on release
follows a predictable trend with lower pH resulting in slower release. This effect starts to
become significant after 3-4 days.
Figure 6D shows that ND-OH released the greatest amount of tiopronin in terms
of percent relative to the amount adsorbed (2.6 - 13.1%) while ND-COOH released 1.8 4.0%, and ND-NH2 released only 0.1 - 1.0%. However, due to the large differences in
adsorption capacity, it is also worth comparing the mass of tiopronin that can be released
per gram of loaded ND. Figure 6E shows that ND-OH also released the greatest amount
of drug per gram of loaded ND (0.68 - 3.3 mg/g) while ND-NH2 released more drug than
an equal weight of ND-COOH (0.14 - 1.4 mg/g from ND-NH2 vs. 0.12 - 0.34 mg/g from
ND-COOH), owing to the large difference in adsorption capacity. Finally, it appears that
prolonged release of tiopronin from ND-OH is possible under neutral or alkaline pH
conditions since the concentration of free tiopronin continues to increase substantially
several days after the start of the desorption experiments. In contrast, acidic conditions
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retard continued release of tiopronin beyond that which is released initially. This trend is
present in each of the functionalized NDs, and the effect can be considered statistically
significant in ND-OH as determined by a Bonferroni post hoc test. This may be
beneficial for delivery of tiopronin and other thiol antioxidants since their premature
oxidation is a concern. ND-OH may slowly release tiopronin in the acidic environment of
the stomach. Blood plasma is buffered at pH 7.4, allowing for increased drug release after
entering the bloodstream. Additionally, weakly acidic formulations may be prepared
which can prevent premature release and oxidation of the drug in topical formulations.

4. CONCLUSION

Adsorption and release of tiopronin is sensitive to the changes of ND surface
chemistry. However, due to the complexity of interactions between surface functional
groups, drug molecules, and the environment, this effect cannot be explained by simply
examining net surface charges. Our results show that ND-OH provides the best balance
between drug capacity and release, making it the best candidate for applications which
benefit from prolonged release of large amounts of tiopronin. Furthermore, formulations
of loaded ND-OH can be prepared at an acidic pH which may be able to prevent
premature release and degradation of tiopronin. ND-COOH has a lower adsorption
capacity but can provide moderate release independent of pH. Additionally, ND-COOH
is easily dispersed due to electrostatic repulsion and high magnitude of Z-potential, so it
may be best suited for applications that require low agglomeration and can benefit from
high surface area of ND. Finally, desorption of tiopronin may not be necessary for all
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applications, so although N D -N H 2 only releases a sm all portion o f its payload, it has a
very high capacity and m ay be useful in applications in w hich it is desirable to have
tiopronin attached on the surface o f dispersed N D for prolonged release or storage in the
body w ith subsequent local release triggered by topical application o f ultrasound, light,
heat, and other stim uli.
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SUPPORTING INFORMATION

M ethodology fo r the preparation o f citrate-phosphate desorption buffers is
provided in T able S1. T he pH 8.1 bu ffer u sed for desorption experim ents w as prepared
by dissolving 1.628 g o f K 2 H P O 4 and 0.089 g o f K H 2 P O 4 in type 1 w ater and then
diluting to a final volum e o f 100 m L in a v olum etric flask as m entioned in Section 2.1.
Sam ple calibration curves used for the determ ination o f M P G in desorption
buffers, as described in Section 2.5, are show n in F igures S2-S5. M atrix effects w ere
significant am ong the different buffers, b u t p eak areas w ere strongly correlated to [M PG]
in each buffer.

T able S1. P reparation o f citrate-phosphate buffers

pH

0.1 M
C itric acid (m L )

0.2 M
N a 2H P O 4 (m L )

4.0

61.45

38.55

5.8

39.55

60.45

7.0

17.65

82.35

7.3

13.05

86.95
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Figure S3. Calibration curve for tiopronin in pH 7.3 desorption buffer

c o u n ts Km in

350000

2 50000

2
150000

R* = 0.9969

1

v= 123194x- 3580

50000

pp m

.00

2.00

3.00

Figure S4. Calibration curve for tiopronin in pH 8.1

3.50

86

REFERENCES

1.

Castaneda-Arriaga, R.; Vivier-Bunge, A.; Raul Alvarez-Idaboy, J. Primary
antioxidant and metal-binding effects of tiopronin: A theoretical investigation of
its action mechanism. Comput. Theor. Chem. 2016, 1077, 48-57.

2.

Kobayashi, S.; Kasuya, M.; Ishii, Y.; Takehana, M.; Sakai, K.; Suzuki, N.; Itoi,
M. Effects of 2-mercaptopropionylglycine on the development of X-ray-induced
cataract in rats. Curr. Eye Res. 1992, 11 (11), 1099-103.

3.

Ichikawa, H.; Imaizumi, K.; Tazawa, Y.; Obara, Y.; Ishikawa, Y.; Tobari, I.;
Tanabe, Y. Effect of tiopronin on senile cataracts. A double-blind clinical study.
Ophthalmologica 1980, 180 (5), 293-8.

4.

Kuck, J. F., Jr.; Kuck, K. D. The Emory mouse cataract: the effects on
cataractogenesis of alpha-tocopherol, penicillamine, triethylenetetramine, and
mercaptopropionylglycine. J. Ocul. Pharmacol. 1988, 4 (3), 243-51.

5.

Zhang, J. G.; Lindup, W. E. Tiopronin protects against the nephrotoxicity of
cisplatin in rat renal cortical slices in vitro. Toxicol. Appl. Pharmacol. 1996, 141
(2), 425-33.

6.

Jarvinen, K.; Jarvinen, T.; Urtti, A. Ocular absorption following topical delivery.
Adv. Drug Del. Rev. 1995, 16 (1), 3-19.

7.

Abdelkader, H.; Alany, R. G.; Pierscionek, B. Age-related cataract and drug
therapy: opportunities and challenges for topical antioxidant delivery to the lens.
J. Pharm. Pharmacol. 2015, 67 (4), 537-50.

8.

Jiang, T.-Y.; Sun, C.-S.; Shen, X.; Wang, T.-Y.; Wang, S.-L. Development of a
poloxamer analogs/bioadhesive polymers-based in situ gelling ophthalmic
delivery system for tiopronin. J. Appl. Polym. Sci. 2009, 114 (2), 775-783.

9.

Hoare, T. R.; Kohane, D. S. Hydrogels in drug delivery: Progress and challenges.
Polymer 2008, 49 (8), 1993-2007.

10.

Mochalin, V. N.; Shenderova, O.; Ho, D.; Gogotsi, Y. The properties and
applications of nanodiamonds. Nat. Nanotechnol. 2011, 7 (111), 11-23.

11.

Turcheniuk, K.; Mochalin, V. N. Biomedical applications of nanodiamond
(Review). Nanotechnology 2017, 28 (25), 252001.

12.

Setyawati, M. I.; Mochalin, V. N.; Leong, D. T. Tuning endothelial permeability
with functionalized nanodiamonds. ACS Nano 2016, 10 (1), 1170-81.

87
13.

Giammarco, J.; Mochalin, V. N.; Haeckel, J.; Gogotsi, Y. The adsorption of
tetracycline and vancomycin onto nanodiamond with controlled release. J.
C o llo id Interface Sci. 2016, 468 , 253-261.

14.

Mochalin, V. N.; Pentecost, A.; Li, X. M.; Neitzel, I.; Nelson, M.; Wei, C.; He,
T.; Guo, F.; Gogotsi, Y. Adsorption of drugs on nanodiamond: toward
development of a drug delivery platform. M ol. Pharm . 2013, 10 (10), 3728-35.

15.

Osswald, S.; Yushin, G.; Mochalin, V.; Kucheyev, S. O.; Gogotsi, Y. Control of
sp2/sp3 carbon ratio and surface chemistry of nanodiamond powders by selective
oxidation in air. J. Am . Chem. Soc. 2006, 128 (35), 11635-42.

16.

Mochalin, V. N.; Neitzel, I.; Etzold, B. J. M.; Peterson, A.; Palmese, G.; Gogotsi,
Y. Covalent incorporation of aminated nanodiamond into an epoxy polymer
network. A C S N a n o 2011, 5 (9), 7494-7502.

17.

Hens, S. C.; Cunningham, G.; Tyler, T.; Moseenkov, S.; Kuznetsov, V.;
Shenderova, O. Nanodiamond bioconjugate probes and their collection by
electrophoresis. D ia m o n d R e la t. M ater. 2008, 17 (11), 1858-1866.

18.

Beltz, J.; Pfaff, A.; Ercal, N. Simultaneous determination of tiopronin and its
primary metabolite in plasma and ocular tissues by HPLC. Biom ed. C hrom atogr.
2018, e4375.

19.

Reineck, P.; Lau, D. W. M.; Wilson, E. R.; Fox, K.; Field, M. R.;
Deeleepojananan, C.; Mochalin, V. N.; Gibson, B. C. Effect of surface chemistry
on the fluorescence of detonation nanodiamonds. A C S N a n o 2017, 11 (11),
10924-10934.

20.

Petit, T.; Puskar, L. FTIR spectroscopy of nanodiamonds: Methods and
interpretation. D ia m o n d R elat. M ater. 2018, 8 9 , 52-66.

21.

Mayo, D. W.; Miller, F. A.; Hannah, R. F. C ourse N o te s on the In terp reta tio n o f
Wiley & Sons, Inc.: 2004.

In fr a r e d a n d R a m a n S p e c tra . John

22.

Petit, T.; Puskar, L.; Dolenko, T.; Choudhury, S.; Ritter, E.; Burikov, S.;
Laptinskiy, K.; Brzustowski, Q.; Schade, U.; Yuzawa, H.; Nagasaka, M.; Kosugi,
N.; Kurzyp, M.; Venerosy, A.; Girard, H.; Arnault, J.-C.; Osawa, E.; Nunn, N.;
Shenderova, O.; Aziz, E. F. Unusual water hydrogen bond network around
hydrogenated nanodiamonds. J. Phys. Chem. C N anom ater. In terfa ces 2017, 121
(9), 5185-5194.

23.

Williams, O. A.; Hees, J.; Dieker, C.; Jager, W.; Kirste, L.; Nebel, C. E. Sizedependent reactivity of diamond nanoparticles. A C S N a n o 2010, 4 (8), 4824-30.

24.

Langmuir, I. The constitution and fundamental properties of solids and liquids.
Part I. Solids. J A C S 1916, 38 (11), 2221-2295.

88

25.

Freundlich, H.; Hatfield, H. C o llo id a n d C apillary C h em istry . Methuen: London,
1926.

26.

Gibson, N. M.; Luo, T.-J. M.; Shenderova, O.; Koscheev, A. P.; Brenner, D. W.
Electrostatically mediated adsorption by nanodiamond and nanocarbon particles.
J. N anopart. Res. 2012, 14 (3).

27.

Hall, K. R.; Eagleton, L. C.; Acrivos, A.; Vermeulen, T. Pore- and solid-diffusion
kinetics in fixed-bed adsorption under constant-pattern conditions. Ind. Eng.
Chem. F undam . 1966, 5 (2), 212-223.

28.

Sun, C.-J.; Sun, L.-Z.; Sun, X.-X. Graphical evaluation of the favorability of
adsorption processes by using conditional langmuir constant. Ind. Eng. Chem.
Res. 2013, 52 (39), 14251-14260.

29.

Turcheniuk, K.; Trecazzi, C.; Deeleepojananan, C.; Mochalin, V. N. Salt-assisted
ultrasonic deaggregation of nanodiamond. A C S A ppl. M ater. In terfa ces 2016, 8
(38), 25461-8.

89

SECTION

2. CONCLUSIONS

Our long term goal is to develop an eye drop formulation that can delay the onset
of cataracts. Antioxidant compounds have the potential to mitigate the oxidative damage
associated with cataractogenesis, but achieving sufficient concentrations in the lens has
proven difficult. In pursuit of this goal, our group is investigating the potential of ND as a
platform for improving MPG residence in the eye and reducing levels of reactive oxygen
species and oxidative damage associated with cataract. Each investigation presented in
this dissertation aimed to address a specific research question.

2.1. TO WHAT EXTENT DOES MPG PROTECT CELLS AGAINST ACUTE
OXIDATIVE INSULT?
Oxidative stress was induced in A549 cells by exposure to 0.6 mM fBHP. In
untreated cells, 0.6 mM fBHP resulted in a significant loss of cell viability due to the
increased generation of intracellular ROS and mitochondrial superoxide, resulting in
GSH depletion. Cells that were simultaneously treated with 0.6 mM fBHP and 5 mM
MPG were comparable to healthy cells; however, lower doses of MPG were much less
effective at preventing cell death. Preservation of cell viability by MPG is most likely the
result of direct ROS scavenging, and it is clear that relatively high doses need to be
maintained in order for MPG to be effective in this model. However, when interpreting
these results, it is important to consider the limitations of the model used. The cells used
in this study were from a human lung carcinoma cell line, which is not intended or
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expected to fully recapitulate human lenses. Furthermore, the intense, short-lived
oxidative insult resulting from incubating the cells in fBHP is not representative of the
gradual damage accumulated over a lifetime of exposure to relatively low concentrations
of oxidants. More complex models studied over a much longer time would be needed in
order to draw any conclusions with respect to anticataract efficacy. These experiments
are reserved for later stages of drug development. Instead, the experiments discussed here
served as a pilot study for establishing a benchmark for MPG's antioxidant activity in a
simplified epithelial cell model. These results can serve as a basis for comparison against
formulations composed of MPG adsorbed onto ND, but investigations with more
complex models are certainly warranted. Future investigations exploring the antioxidant
activity of MPG vs. ND:MPG will utilize human lens epithelial cells, corneal epithelial
cells, and animal models.

2.2. HOW WILL MPG BE MEASURED IN CELL AND ANIMAL MODELS?
An HPLC method was developed for the determination of MPG and MPA in
ocular tissues and other matrices. Pre-column derivatization and fluorescence detection
allowed for high sensitivity, and the use of a 4.6-pm core-shell stationary phase resulted
in rapid separation. Method validation experiments demonstrated that this method would
be suitable for monitoring MPG uptake and residence in the lens and cornea. Other
methods were available for MPG, but they were not suitable for our application either
due to sensitivity limitations or matrix interferences. This method is a necessary tool for
determining the efficacy of various drug delivery vehicles, as well as the fate of MPG
after administration to the eye. This method offers simultaneous determination of MPA,
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the primary metabolite of MPG. One of the primary reasons MPG was selected for
investigating ND-mediated delivery is that it is metabolized to MPA, making its fate easy
to track. Other thiol drug candidates may be more effective as antioxidants, such as the
GSH prodrug N-acetylcysteine amide (NACA) because they can increase the size of the
total GSH pool in addition to directly scavenging ROS. However, NACA is de-acetylated
in vivo to N-acetylcysteine (NAC), which is then further metabolized to cysteine, which
is used not only for GSH synthesis but also for a number of other biological reactions.
Tracking all of these metabolites without radiolabeling would be very difficult and
resource-intensive. In contrast, MPG and MPA are not found in untreated human or
animal lenses, making efforts to track MPG far more reliable.

2.3. WHAT IS THE OPTIMAL ND SURFACE CHEMISTRY FOR ADSORPTION
AND RELEASE OF MPG?
Nanodiamond powder was functionalized to produce ND-COOH, ND-OH, and
ND-NH2, and the effect of surface chemistry on adsorption and desorption of MPG was
determined. It would seem from these experiments that ND-OH is the most promising
candidate for ND-mediated delivery of tiopronin. The ND-OH provided the best balance
between adsorption capacity and sustained release. Furthermore, its release was shown to
be the most strongly influenced by pH. Relatively low amounts of MPG were released
from ND-OH in slightly acidic conditions, even after 12 days, but ND-OH released large
amounts of MPG at physiological pH (7.4) and under slightly basic conditions. Since the
cornea can tolerate eye drop formulations as acidic as pH 4, acidic preparations of NDOH:MPG can prevent premature release and degradation of MPG. Upon administration
to the eye, the pH will equilibrate with that of the ocular surface and tear film, triggering
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prolonged release o f greater am ounts o f M PG . F inally, N D -O H exhibits a positive Zpotential at physiological pH , w hich m ay help prolong retention o f N D -O H :M P G on the
cornea due to electrostatic attraction to the negatively charged corneal surface.
A lthough N D -O H seem s like a clear choice fo r N D -m ediated delivery o f M PG ,
there are other factors to consider w hen optim izing N D surface chem istry fo r this
application. F o r exam ple, it is u n clear at this tim e w h eth er or not M P G needs to be
desorbed from the N D in order to act as a scavenger o f R O S. I f adsorption to N D does
not im pede antioxidant activity, then N D -N H 2 m ay perform even better th an N D -O H
since N D -N H 2 can carry significantly greater am ounts o f M PG .

2.4. FUTURE DIRECTIONS
T he contents o f this dissertation represent the prelim inary w ork necessary fo r the
developm ent and evaluation o f N D fo r delivery o f M P G to the eye. The tools developed
here w ill play an integral role in the assessm ent o f N D efficacy. M ov in g forw ard, several
factors need to be considered fo r the successful application o f N D :M P G in eye drop
form ulations aim ed at delaying cataract. F irstly, it is im portant to investigate the effect o f
N D on the antioxidant activity o f M P G to ensure th at the N D does not hinder its ability to
scavenge R O S and to determ ine w h eth er N D can preserve or even prom ote the action o f
M PG . A nother key step forw ard is to determ ine the effect o f N D on corneal penetration
and lenticular uptake o f M P G w ith appropriate cell and anim al m odels.
A fter optim ization o f the N D :M P G eye drop form ulation, it should be tested in an
anim al m odel o f age-related nuclear cataract. A s o f now , there is no anim al or cell m odel
th at fully recapitulates every relevant feature o f hum an cataractogenesis; how ever, the
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Emory mouse model is recommended. Cataract development in these animals mimics
important features of human age-related nuclear cataract. In contrast with models that
employ short-lived, high-intensity oxidative insults to induce cataracts, Emory mice
develop cataracts spontaneously over the course of 5-6 months. This gradual progression
provides a window for monitoring pre-cataractous changes and the effects of preventative
treatments.
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